MIDWEST COMPANION

New Practice PROGRAMS

2026

Addison Biological Laboratory, Inc.

"New" Practice Program

Definition of a "New" Practice:
Any practice that is built from scratch or that has completely changed ownership.

Description of Program:
We will supply product for product (one purchased = one free) on the initial order for any new or new satellite practice. There are no minimum or maximum requirements with this program and it includes all of our *MAXI/GUARD®* products. This is a free goods program and we will ship the free goods from our office to the practice. For approval, simply fax, e-mail or mail the new practice's information and order amount to Karlin Yaeger, Global Sales Manager.

Addison Biological Laboratory, Inc. reserves the right to change this program at anytime and without written notice.

Addison Biological Laboratory, Inc.
507 North Cleveland Avenue
Fayette, MO 65248
800-331-2530
Fax:660-248-2554
info@addisonlabs.com
www.addisonlabs.com

midwest veterinary supply

THE FUTURE OF REUNITING LOST PETS IS HERE!

BuddyID®

NEW CLINIC OFFER*

BUY

2 cases of the BuddyID® Complete Protection System + Temp - *25 ct.*

AND

2 cases of the BuddyBadge® Collar Tags - *12 ct.*

FREE! ($399 Value)

RECEIVE A FREE

Microchip + Temp Scanner ($399 value)

*Offer available for new clinics only. New clinic defined as not having ordered product in the previous 12 months.

Creative Science®

888.506.3039 www.creative.science

Join the Growing List of Veterinarians Switching to PetLink

NEW PRACTICE OPENING OFFER PROMO

Buy 2 boxes of
25 PetLink Slim microchips,
get a COMPACT MAX
Universal Scanner **FREE!**

✓ **PetLink Slim microchips**
$15.50/microchip;
$387.50/box.

✓ **Includes Free Lifetime Registration with PetLink.net**
No renewal or annual fees required!

✓ **COMPACT MAX Universal Scanner**
This portable universal scanner scans all microchip types with simple, one-button operation.
A $249 value!

*Valid only for brand new brick and mortar or new mobile veterinary practice, or clinics making initial Datamars microchip purchase under new ownership. Order must be placed within 12 months of opening. 2 boxes must appear on one invoice and are not returnable. Limit 1 per customer.

Please contact your preferred Distribution Sales Representative for more information.

Contact us at
1-877-PETLINK (738-5465)

or email us at
petlink@petlink.net

www.petlink.net
ussales@datamars.com

PetLink™
a DATAMARS brand

July 1, 2025
Program Code: NWCL

New Clinic Buy 1, Get 1 Free Promotion

Clinic Name: _____

Veterinarian(s): _____

Address: _____

City: _____ State: _____ Zip: _____

Phone: _____ Fax: _____ Email: _____

Offer Restrictions

This promotion does not have an expiration date. Dechra will notify if any updates or changes are made.

1. New practice is defined as: A veterinary hospital (mobile or stand-alone), opened or purchased within the last 90 days, that is owned and/or operated by a licensed veterinarian and has active Veterinarian-Client-Patient Relationships (VCPR) (i.e. retail locations without a veterinarian on the premise are NOT eligible). Dechra reserves the right to change, cancel or refuse this program at any time.
2. See page 2 for qualifying products.
3. All new clinic orders must be approved by the local Dechra Territory Manager. If the clinic is in an open territory, the order must be approved by the Dechra Inside Representative. The order is subsequently submitted to a partnering Distribution Sales Representative of the clinic's choice.
4. Distribution Partners are to utilize the "NWCL" program code.
5. All qualifying products must be purchased in a single order.
6. Offer cannot be combined with any other promotional offer and is a one-time offer for new practices.
7. Distribution Partners will ship free goods. Orders may come in multiple shipments.
8. All Dechra products are subject to the Dechra Return Goods Policy. Dechra will not accept returns for expired products purchased on promotion. FDA-approved Dechra Products are not eligible to be returned, unless damaged or defective upon delivery. Check with your Distribution Representative for more details.
9. All personal information will be handled in accordance with Dechra's Privacy Policy.

Dechra Veterinary Products, 7015 College Blvd., Suite 525, Overland Park, KS 66211
Customer Service: (866) 683-0660
24-hour Veterinary Technical Support (866) 933-2472 | support@dechra.com | dechra-us.com

July 1, 2025
Program Code: NWCL

New Clinic Buy 1, Get 1 Free Promotion

Qualifying Products List

Item	Description	Size	Qty Ordered
FELINE KIDNEY HEALTH			
17033-065-30	Porus® One	500 mg packets, 30 ct	
CATONE-520	Catney® One	520 mg packets, 30 ct	
ANTI-INFECTIVES — TOPICAL			
122-75	Animax® Ointment (nystatin-neomycin sulfate-thiostrepton-triamcinolone acetonide ointment)	7.5 mL tube	
122-15	Animax® Ointment	15 mL tube	
122-30	Animax® Ointment	30 mL tube	
420-15	Muricin® (mupirocin ointment) 2%	15 gram tube	
335-60	GENTACALM® Topical Spray (gentamicin sulfate, USP with betamethasone valerate, USP)	60 mL bottle	
335-12	GENTACALM® Topical Spray	120 mL bottle	
ANTI-INFECTIVES — OTIC TREATMENT			
17033-283-20	Osurnia® (florfenicol, terbinafine, betamethasone acetate)	20 x 1 mL tubes	
DUOTIC-02	DuOtic® (terbinafine and betamethasone acetate otic gel)	2 x 1 mL tubes	
DUOTIC-20	DuOtic®	20 x 1 mL tubes	
DERMATOLOGY — OTIC CLEANSERS			
EKW	EpiKlean® Ear Cleanser	8 oz bottle	
12EKW	EpiKlean® Ear Cleanser	12 oz bottle	
32EKW	EpiKlean® Ear Cleanser	32 oz bottle	
KOW	KlearOtic Ear Cleanser	4 oz bottle	
APW	MalAcetic® Otic Cleanser	4 oz bottle	
8APW	MalAcetic® Otic Cleanser	8 oz bottle	
16APW	MalAcetic® Otic Cleanser	16 oz bottle	
MUW	MalAcetic ULTRA® Otic Cleanser	2 oz bottle	
8MUW	MalAcetic ULTRA® Otic Cleanser	8 oz bottle	
DERMATOLOGY — EAR AND SKIN FLUSHES			
MKTW	Mal-A-Ket® Plus TrizEDTA® Flush	4 oz bottle	
12MKTW	Mal-A-Ket® Plus TrizEDTA® Flush	12 oz bottle	
TPW	TrizCHLOR® Flush	4 oz bottle	
TZAQW	TrizEDTA® Aqueous Flush	4 oz bottle	
16TZAQW	TrizEDTA® Aqueous Flush	16 oz bottle	
TUW	TrizUltra+Keto® Flush	4 oz bottle	
12TUW	TrizUltra+Keto® Flush	12 oz bottle	
MALFLUSH-4	Malaseb® Flush	4 oz bottle	
MALFLUSH-12	Malaseb® Flush	12 oz bottle	

Item	Description	Size	Qty Ordered
DERMATOLOGY — SHAMPOOS/CONDITIONERS/MOUSSES			
12BPPW	DermaBenSs® Shampoo	12 oz bottle	
GBPPW	DermaBenSs® Shampoo	Gallon bottle	
12OSW	DermAllay Oatmeal Shampoo	12 oz bottle	
GOSW	DermAllay Oatmeal Shampoo	Gallon bottle	
OCW	DermAllay Oatmeal Spray Conditioner	8 oz bottle	
12OCW	DermAllay Oatmeal Spray Conditioner	12 oz bottle	
GOCW	DermAllay Oatmeal Spray Conditioner	Gallon bottle	
12CSW	DermaLyte® Shampoo	12 oz bottle	
GCSW	DermaLyte® Shampoo	Gallon bottle	
MKW	Mal-A-Ket® Shampoo	8 oz bottle	
GMKW	Mal-A-Ket® Shampoo	Gallon bottle	
MKTSW	Mal-A-Ket® Plus TrizEDTA® Spray Conditioner	8 oz bottle	
MHTW	MiconaHex+Triz® Shampoo	8 oz bottle	
16MHTW	MiconaHex+Triz® Shampoo	16 oz bottle	
GMHTW	MiconaHex+Triz® Shampoo	Gallon bottle	
MHTCW	MiconaHex+Triz® Spray Conditioner	8 oz bottle	
16MHTCW	MiconaHex+Triz® Spray Conditioner	16 oz bottle	
MHTMW	MiconaHex+Triz® Mousse	7.1 oz bottle	
TCSW	TrizCHLOR® 4 Shampoo	8 oz bottle	
16TCSW	TrizCHLOR® 4 Shampoo	16 oz bottle	
GTCSW	TrizCHLOR® 4 Shampoo	Gallon bottle	
TCCW	TrizCHLOR® 4 Spray Conditioner	8 oz bottle	
TCMW	TrizCHLOR® 4 Mousse	7.1 oz bottle	
TCCHW	TrizCHLOR® 4HC Spray Conditioner	8 oz bottle	
ATOP-M84	Atopivet® Mousse	8.45 oz bottle	
MALSHAM-8	Malaseb® Shampoo	8 oz bottle	
MALSHAM-16	Malaseb® Shampoo	16 oz bottle	
MALSPRAY-8	Malaseb® Spray	8 oz bottle	

July 1, 2025
Program Code: NWCL

Dechra

New Clinic Buy 1, Get 1 Free Promotion

Qualifying Products List

Item	Description	Size	Qty Ordered
DERMATOLOGY — WIPES			
FPW	MalAcetic® Wet Wipes	6" x 8", 25 count pack	
BWWW	MalAcetic® Wet Wipes	5" x 6", 100 count jar	
WMKW	Mal-A-Ket® Wipes	2.25" round, 50 count jar	
MHTWW	MiconaHex+Triz® Wipes	2.25" round, 50 count jar	
TCW	TrizCHLOR® 4 Wipes	2.25" round, 50 count jar	
DERMATOLOGY — COLLAR, SPOT-ON			
ATOP-SPOT8	Atopivet® Spot-On	8 x 2 mL pipettes	
ATOP-SMCOL	Atopivet® Skin Care Collar	13" collar, < 15 lbs	
ATOP-LGCOL	Atopivet® Skin Care Collar	29" collar, > 15 lbs	
FATTY ACIDS			
FFACS60	Eicosa3FF® SnipCaps - Small	<60 lbs, 60 count	
FFACS120	Eicosa3FF® SnipCaps - Small	<60 lbs, 120 count	
FFACL60	Eicosa3FF® SnipCaps - Large	>30 lbs, 60 count	
FFACL120	Eicosa3FF® SnipCaps - Large	>30 lbs, 120 count	
20OFAW	EicosaCaps® Omega 3 & 6 Capsules - Small	<40 lbs, 60 count	
60OFAW	EicosaCaps® Omega 3 & 6 Capsules - Large	41-70 lbs, 60 count	
ECW	EicosaDerm® Omega 3 Liquid	8 oz pump bottle	
32ECW	EicosaDerm® Omega 3 Liquid	32 oz pump bottle	
SUPPLEMENTS			
084-27	CAT LAX®	56.7 gram tube	
285-12	Redonyl® Ultra Soft Chews	100 mg, 120 count tub	
288-12	Redonyl® Ultra Soft Chews	200 mg, 120 count tub	
17033-020-20	ProbioWrap™ Pill Wrap Paste with Probiotics	4.2 oz jar	

Item	Description	Size	Qty Ordered
PHYCOX® CANINE JOINT SUPPLEMENTS			
PSB	Phycox® Joint Supplement Small Bites	120 count tub	
PSBHA	Phycox® HA HypoAllergenic Joint Supplement Small Bites	120 count tub	
PSBMAX	Phycox® MAX Joint Supplement Small Bites	120 count tub	
PSC-060	Phycox® Joint Supplement Soft Chews	60 count tub	
PSC-120	Phycox® Joint Supplement Soft Chews	120 count tub	
PSCMAX	Phycox® MAX Joint Supplement Soft Chews	90 count tub	
PSCHA	Phycox® HA HypoAllergenic Joint Supplement Soft Chews	120 count tub	
PSCHAMAX	Phycox® HA HypoAllergenic MAX Joint Supplement Soft Chews	90 count tub	
DENTAL PRODUCTS			
DCW-0022	DENTEES® Chews	12 oz bag	
DSW-0023	DENTEES® Stars	4 oz bag	
533-65	VETRADENT® Toothpaste *(Toothbrush included)*	2.3 oz tube	
535-30	VETRADENT® Rawhide Dental Chews for Dogs *(11-25lbs)*	30 ct bag	
536-30	VETRADENT® Rawhide Dental Chews for Dogs *(26-65lbs)*	30 ct bag	
532-03	VETRADENT® Powder Water Additive *(VOHC Seal of Acceptance)**	300 gram tub	
530-05	VETRADENT® Water Additive *(VOHC Seal of Acceptance)**	17 oz bottle	
531-60	VETRADENT® Dental Spray	2 oz bottle	
534-60	VETRADENT® Dental Wipes	60 count jar	
*achieved in dogs only; achieved with once monthly brushing in accordance with study.			
OPHTHALMICS			
17033-046-10	OphtHAvet® Complete Ophthalmic Gel	10 mL bottle	
17033-047-05	OphtHAvet® Ophthalmic Ointment	5 gm tube	
17033-045-10	OphtHAvet® Ophthalmic Solution	10 mL bottle	
211-38	PURALUBE® Vet Ointment (petrolatum ophthalmic ointment)	3.5 gram tube	

July 1, 2025
Program Code: NWCL

New Clinic Buy 2, Get 1 Free Promotion

Clinic Name: _____

Veterinarian(s): _____

Address: _____

City: _____ State: _____ Zip: _____

Phone: _____ Fax: _____ Email: _____

Veterinary License Number: _____

Offer Restrictions

This promotion does not have an expiration date. Dechra will notify if any updates or changes are made.

1. A new practice is defined as: A veterinary hospital (mobile or stand-alone), opened or purchased within the last 90 days, that is owned and/or operated by a licensed veterinarian and has active Veterinarian-Client-Patient Relationships (VCPR) (i.e. retail locations without a veterinarian on the premise are NOT eligible). Dechra reserves the right to change, cancel or refuse this program at any time.
2. Any new veterinary practice can buy 2, get 1 free, on qualifying Dechra Veterinary products (like for like, no mix/match).
3. See page 4 for qualifying products.
4. All new clinic orders must be approved by the local Dechra Territory Manager. If the clinic is in an open territory, the order must be approved by the Dechra Inside Representative. The order is subsequently submitted to a partnering Distribution Sales Representative of the clinic's choice.
5. Distribution Partners are to utilize the "NWCL" program code.
6. All qualifying products must be purchased in a single order.
7. Offer cannot be combined with any other promotional offer and is a one-time offer for new practices.
8. Distribution Partner will ship free goods. Orders may come in multiple shipments.
9. All Dechra products are subject to the Dechra Return Goods Policy. Dechra will not accept returns for expired products purchased on promotion. FDA-approved Dechra Products are not eligible to be returned, unless damaged or defective upon delivery. Check with your Distribution Representative for more details.
10. All personal information will be handled in accordance with Dechra's Privacy Policy.

July 1, 2025
Program Code: NWCL

New Clinic Buy 2, Get 1 Free Promotion

Qualifying Products List

Item	Description	Size	Qty Ordered
ONCOLOGY			
LBL-7004-00	Laverdia®-CA1 (verdinexor tablets)	2.5 mg, 50 count	
LBL-7005-00	Laverdia®-CA1	10 mg, 50 count	
LBL-7010-00	Laverdia®-CA1	50 mg, 16 count	
LBL-7006-00	Laverdia®-CA1	50 mg, 50 count	
ENDOCRINOLOGY			
Fel-025	Felimazole® Coated Tablets (methimazole tablets)	2.5 mg, 100 count	
Fel-050	Felimazole® Coated Tablets	5.0 mg, 100 count	
Vet-005	VETORYL® Capsules (trilostane)	5 mg, 30 count	
Vet-010	VETORYL® Capsules	10 mg, 30 count	
Vet-020	VETORYL® Capsules	20 mg, 30 count	
Vet-030	VETORYL® Capsules	30 mg, 30 count	
Vet-060	VETORYL® Capsules	60 mg, 30 count	
Vet-120	VETORYL® Capsules	120 mg, 30 count	
382-04	ZYCORTAL® Suspension (desoxycorticosterone pivalate injectable suspension)	25 mg/mL, 4 mL vial	
FELINE WEIGHT MANAGEMENT			
86078-686-01	Mirataz® (mirtazapine transdermal ointment)	5 gram tube	
ANTIEMETIC			
EMPVST-16	Emeprev (maropitant citrate) Tablets	16 mg, 4 ct strip	
EMPVST-24	Emeprev Tablets	24 mg, 4 ct strip	
EMPVST-60	Emeprev Tablets	60 mg, 4 ct strip	
EMPVST-160	Emeprev Tablets	160 mg, 4 ct strip	
EMPVBT-16	Emeprev Tablets	16 mg, 60 ct bottle	
EMPVBT-24	Emeprev Tablets	24 mg, 60 ct bottle	
EMPVBT-60	Emeprev Tablets	60 mg, 60 ct bottle	
EMPVBT-160	Emeprev Tablets	160 mg, 60 ct bottle	

Item	Description	Size	Qty Ordered
ANTI-INFECTIVES — SYSTEMIC			
17033-440-07	Clavacillin® (amoxicillin and clavulanate potassium tablets), USP Veterinary Tablets	62.5 mg, 70 count	
17033-441-07	Clavacillin® Veterinary Tablets	125 mg, 70 count	
17033-442-07	Clavacillin® Veterinary Tablets	250 mg, 70 count	
17033-443-07	Clavacillin® Veterinary Tablets	375 mg, 70 count	
17033-440-21	Clavacillin® Veterinary Tablets	62.5 mg, 210 count	
17033-441-21	Clavacillin® Veterinary Tablets	125 mg, 210 count	
17033-442-21	Clavacillin® Veterinary Tablets	250 mg, 210 count	
17033-443-21	Clavacillin® Veterinary Tablets	375 mg, 210 count	
17033-451-15	Clavacillin® (amoxicillin and clavulanate potassium for oral suspension), USP Drops	15 mL bottle	
17033-431-10	Cefpoderm® (cefpodoxime proxetil tablets)	100 mg, 100 count	
17033-432-10	Cefpoderm® Tablets	200 mg, 100 count	
EFT22-100	Enroquin® (enrofloxacin) Flavored Tablets	22.7 mg, 100 count	
EFT22-500	Enroquin® Flavored Tablets	22.7 mg, 500 count	
EFT68-50	Enroquin® Flavored Tablets	68 mg, 50 count	
EFT68-250	Enroquin® Flavored Tablets	68 mg, 250 count	
EFT136-50	Enroquin® Flavored Tablets	136 mg, 50 count	
EFT136-200	Enroquin® Flavored Tablets	136 mg, 200 count	
ENROINJ22-20	Enroquin® (enrofloxacin) Antibacterial Injectable Solution 2.27%	22.7 mg/mL, 20 mL vial	
17033-125-10	Marboquin® (marbofloxacin) Tablets	25 mg, 100 count	
17033-125-25	Marboquin® Tablets	25 mg, 250 count	
17033-126-10	Marboquin® Tablets	50 mg, 100 count	
17033-126-25	Marboquin® Tablets	50 mg, 250 count	
17033-127-50	Marboquin® Tablets	100 mg, 50 count	

July 1, 2025
Program Code: NWCL

New Clinic Buy 2, Get 1 Free Promotion

Qualifying Products List

Item	Description	Size	Qty Ordered
ANTI-INFECTIVES — SYSTEMIC (CONTINUED...)			
MT25-100	Marboquin® Chewable Tablets (marbofloxacin)	25 mg, 100 count	
MT25-250	Marboquin® Chewable Tablets	25 mg, 250 count	
MT50-100	Marboquin® Chewable Tablets	50 mg, 100 count	
MT50-250	Marboquin® Chewable Tablets	50 mg, 250 count	
MT100-50	Marboquin® Chewable Tablets	100 mg, 50 count	
MT200-50	Marboquin® Chewable Tablets	200 mg, 50 count	
ANTI-INFECTIVES — OTIC TREATMENT			
MMET-75	Mometavet® (gentamicin sulfate, mometasone furoate anhydrous, and clotrimazole otic suspension)	7.5 gram bottle	
MMET-15	Mometavet®	15 gram bottle	
MMET-30	Mometavet®	30 gram bottle	
MMET-215	Mometavet®	215 gram bottle	
IMMUNOSUPPRESSANT			
SPOR25-15	Sporimune® (cyclosporine capsules) USP MODIFIED	25 mg, 15 count	
SPOR50-15	Sporimune®	50 mg, 15 count	
SPOR100-15	Sporimune®	100 mg, 15 count	
SURGICAL SUITE — ANESTHETICS/SEDATIVES			
ZEN-10	Zenalpha® (medetomidine and vatinoxan hydrochlorides injection)	0.5 mg & 10 mg/mL, 10 mL vial	
17033-005-10	Dexmedesed® (dexmedetomidine hydrochloride) Sterile Injectable Solution	0.5 mg/mL, 10 mL vial	
KET-10	Ketamine Hydrochloride Injection	100 mg/mL, 10 mL vial	
17033-010-05	Tzed® (tiletamine and zolazepam for injection)	100 mg/mL, 5 mL vial	
ISO-250	Isospire® (isoflurane) Inhalation Anesthetic	250 mL bottle	
17033-092-25	Sevospire™ (sevoflurane) Inhalation Anesthetic	250 mL bottle	

Item	Description	Size	Qty Ordered
EUTHANASIA			
EUTHSOL-100	Euthaphen® (pentobarbital sodium and phenytoin sodium) Euthanasia Solution	100 mL vial	
PAIN MANAGEMENT/NSAIDS			
FIRO57-60	Firovet™ (firocoxib) Chewable Tablets	57 mg, 60 count	
FIRO57-18	Firovet™ (firocoxib) Chewable Tablets	57 mg, 180 count	
FIRO227-60	Firovet™ (firocoxib) Chewable Tablets	227 mg, 60 count	
FIRO227-18	Firovet™ (firocoxib) Chewable Tablets	227 g, 180 count	
MELINJ05-10	Meloxivet™ (meloxicam) Solution for Injection	5 mg/mL, 10 mL vial	
MELINJ05-02	Meloxivet™ Solution for Injection	5mg/mL, 20mL vial	
CARPINJ50-20	Carprovet® (carprofen) Injectable	50mg/mL, 20mL vial	
CCAP25-60	Carprovet® (carprofen tablets) Caplets	25 mg, 60 count	
CCAP25-180	Carprovet® Caplets	25 mg, 180 count	
CCAP75-60	Carprovet® Caplets	75 mg, 60 count	
CCAP75-180	Carprovet® Caplets	75 mg, 180 count	
CCAP100-60	Carprovet® Caplets	100 mg, 60 count	
CCAP100-180	Carprovet® Caplets	100 mg, 180 count	
CCH25-30	Carprovet® (carprofen) Chewable Tablets	25 mg, 30 count	
CCH25-60	Carprovet® Chewable Tablets	25 mg, 60 count	
CCH25-180	Carprovet® Chewable Tablets	25 mg, 180 count	
CCH75-30	Carprovet® Chewable Tablets	75 mg, 30 count	
CCH75-60	Carprovet® Chewable Tablets	75 mg, 60 count	
CCH75-180	Carprovet® Chewable Tablets	75 mg, 180 count	
CCH100-30	Carprovet® Chewable Tablets	100 mg, 30 count	
CCH100-60	Carprovet® Chewable Tablets	100 mg, 60 count	

Dechra

New Clinic Buy 2, Get 1 Free Promotion

Qualifying Products List

Item	Description	Size	Qty Ordered
PAIN MANAGEMENT/NSAIDS (CONTINUED...)			
CCH100-180	Carprovet® Chewable Tablets	100 mg, 180 count	
CTAB25-60	Carprovet® (carprofen tablets) Flavored Tablets	25 mg, 60 count	
CTAB25-180	Carprovet® Flavored Tablets	25 mg, 180 count	
CTAB75-60	Carprovet® Flavored Tablets	75 mg, 60 count	
CTAB75-180	Carprovet® Flavored Tablets	75 mg, 180 count	
CTAB100-60	Carprovet® Flavored Tablets	100 mg, 60 count	
CTAB100-180	Carprovet® Flavored Tablets	100 mg, 180 count	
RED12-30	Rederox® (deracoxib) Chewable Tablets	12 mg, 30 count	
RED12-90	Rederox® Chewable Tablets	12 mg, 90 count	
RED25-30	Rederox® Chewable Tablets	25 mg, 30 count	
RED25-90	Rederox® Chewable Tablets	25 mg, 90 count	
RED75-30	Rederox® Chewable Tablets	75 mg, 30 count	
RED75-90	Rederox® Chewable Tablets	75 mg, 90 count	
RED100-30	Rederox® Chewable Tablets	100 mg, 30 count	
RED100-90	Rederox® Chewable Tablets	100 mg, 90 count	
EQUINE PRODUCTS			
OSPHOS	OSPHOS® (clodronate injection)	15 mL vial	
Equ-025S	EQUIDONE® Gel (domperidone)	25 mL syringe	
SUCROMATE-10	SucroMate® Equine (deslorelin acetate) Sterile Suspension	10 mL vial	
110irap	Orthokine® vet irap 10	1 kit (three 10 mL syringes)	
100irap-eq	Orthokine® vet irap 60	1 kit (one 60 mL syringe)	
TORP10-10	Torphadine® (butorphanol tartrate injection)	10 mg/mL, 10 mL vial	
BUT-10	Torphadine®	10 mg/mL, 50 mL vial	
ROMP100-50	Rompun® (xylazine injection)	50 mL vial	
IVERMEC-60	Ivermectin Paste 1.87%	6.08 gram syringe	
ZYCO250-75	Zycosan® (pentosan polysulfate sodium injection)	4 x 7.5 mL vials	

midwest veterinary supply

CONGRATULATIONS
ON YOUR NEW VETERINARY PRACTICE!

As a trusted partner of veterinarians, Elanco knows that opening a new practice is a challenge and we want to help by offering you a big discount on your first order.

Please contact your Elanco Sales Representative to see if you qualify for the Elanco New Practice Program. We want to assist you in stocking your new practice with the products that will help you provide the best options for the animals in your care.

Please check all that apply:

- ☐ Licensed Veterinarian
- ☐ Existing practice with a new build
- ☐ Building a new hospital
- ☐ Opening a satellite clinic at a new address
- ☐ Complete ownership change
- ☐ Practice operates at a fixed business address
- ☐ Existing practice expanding into treatment of pets
- ☐ Not owned by a multi-practice corporate entity
- ☐ Practice has been open less than 180 days

Take the following steps to ensure your new practice savings:

1. Contact your Elanco Sales Representative to confirm your eligibility
2. Complete the application for a new account with Elanco: https://secure.inetcreditexchange.com/viewform/elanco
3. Work with your Elanco Sales Representative to complete the New Practice Program order

Elanco™

PLACE A NEW PRACTICE PROGRAM ORDER AND RECEIVE FREE GOODS FROM ELANCO

Products	Limits
advantus® (imidacloprid) soft chew For complete directions for use and safety information see product label. Advantage® XD Cheristin® for cats spinetoram Comfortis® (spinosad) MilbeMite® OTIC Solution (0.1% milbemycin oxime) advantage multi® (imidacloprid+moxidectin) Advantage® II K9 Advantix® II Credelio® (lotilaner) Credelio® CAT (lotilaner) Credelio® Quattro® (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) Interceptor® (milbemycin oxime) INTERCEPTOR® PLUS (milbemycin oxime/praziquantel) Seresto® Trifexis® (spinosad+milbemycin oxime)	Max of 2 free cartons per SKU* *Match free goods to purchased goods
Atopica® (cyclosporine capsules) USP MODIFIED Baytril® (enrofloxacin) CLARO® (florfenicol, terbinafine, mometasone furoate) Otic Solution Deramaxx® (deracoxib) Droncit® (praziquantel) Drontal® Plus (praziquantel/pyrantel pamoate/febantel) Tablets Drontal® (praziquantel/pyrantel pamoate) Elura™ (capromorelin oral solution) Entyce® (capromorelin oral solution) Galliprant® (grapiprant tablets) onsior® (robenacoxib) Percorten®-V (desoxycorticosterone pivalate injectable suspension) Topical Solution profender® (emodepside/praziquantel) Surolan® (miconazole nitrate, polymyxin B sulfate, prednisolone acetate) quellin® (carprofen) soft chewable tablets Veraflox® (pradofloxacin) Oral Suspension for Cats Varenzin-CA1® (molidustat oral suspension) Bexacat® (bexagliflozin tablets) Before using Bexacat, it is important to read the entire package insert including the **boxed warning.** Zenrelia® (ilunocitinib tablets) Before using Zenrelia, it is important to read the entire package insert including the **boxed warning.**	Max of $2,500 in free goods* (mix/match) *Match free goods to purchased goods
truCan™ truFel™ truCan™ ultra truFel™ ultra Rabvac™	Max of 500 free doses* (mix/match) *Match free goods to purchased goods

BEXACAT INDICATION:
Bexacat is indicated to improve glycemic control in otherwise healthy cats with diabetes mellitus not previously treated with insulin.

BEXACAT IMPORTANT SAFETY INFORMATION:
Before using Bexacat, you must read the entire package insert, including the boxed warning. Call 1-888-545-5973 or visit https://www.elancolabels.com/us/bexacat for complete safety information.

Cats treated with Bexacat may be at an increased risk of diabetic ketoacidosis or euglycemic diabetic ketoacidosis, both of which may result in death. Development of these conditions should be treated promptly, including insulin administration and discontinuation of Bexacat. Do not use Bexacat in cats with diabetes mellitus who have previously been treated with insulin, who are receiving insulin, or in cats with insulin-dependent diabetes mellitus. The use of Bexacat in cats with insulin-dependent diabetes mellitus, or the withdrawal of insulin and initiation of Bexacat, is associated with an increased risk of diabetic ketoacidosis or euglycemic diabetic ketoacidosis and death. Sudden onset of hyporexia/anorexia, lethargy, dehydration, diarrhea that is unresponsive to conventional therapy, or weight loss in cats receiving Bexacat should prompt immediate discontinuation of Bexacat and assessment for diabetic ketoacidosis, regardless of blood glucose level. Bexacat should not be initiated in cats with pancreatitis, anorexia, dehydration, or lethargy at the time of diagnosis of diabetes mellitus, as it may indicate the presence of other concurrent disease and increase the risk of diabetic ketoacidosis. Due to risk of severe adverse reactions, do not use Bexacat in cats with evidence of hepatic disease or reduced renal function. Consult a physician in case of accidental ingestion by humans.

ZENRELIA INDICATION:
Zenrelia is indicated for control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.

ZENRELIA IMPORTANT SAFETY INFORMATION:
Read the entire package insert before using this drug, including the Boxed Warning.
For Full prescribing information call 1-888-545-5973 or visit www.elancolabels.com/us/zenrelia

WARNING: VACCINE-INDUCED DISEASE AND INADEQUATE IMMUNE RESPONSE TO VACCINES. Based on results of the vaccine response study, dogs receiving Zenrelia are at risk of fatal vaccine-induced disease and inadequate immune response to vaccines. Discontinue Zenrelia for at least 28 days to 3 months prior to vaccination and withhold Zenrelia for at least 28 days after vaccination. Dogs should be up to date on vaccinations prior to starting Zenrelia. Do not use in dogs less than 12 months old or dogs with a serious infection. Monitor dogs for infections because Zenrelia may increase susceptibility to opportunistic infections. Neoplastic conditions (benign and malignant) were observed during clinical studies. Consider the risks and benefits of treatment in dogs with a history of recurrence of these conditions. The most common adverse reactions were vomiting, diarrhea and lethargy. Zenrelia has not been evaluated in breeding, pregnant, or lactating dogs and concurrent use with glucocorticoids, cyclosporine, or other systemic immunosuppressive agents has not been tested. For full prescribing information see package insert.

PLEASE SEE TERMS AND CONDITIONS ON THE NEXT PAGE

Elanco™

NEW PRACTICE PROGRAM TERMS & CONDITIONS

- "New Practice" refers to a small/mixed animal practice, with a brick-and-mortar location employing licensed, practicing veterinarians in a bona-fide veterinarian-client patient relationship (VCPR), that has submitted a new account request with Elanco and been approved by Elanco as a new practice within one hundred and eighty (180) days of the practice opening. A New Practice does not include practices owned by a multi-practice corporate entity.
- This offer is open to veterinary clinics, practices, and hospitals in the US only.
- A single Elanco New Practice Program order must be placed directly with their Elanco Sales Representative; an authorized distribution agent must be identified with the order.
- Any orders placed directly with an authorized distribution agent will not be considered an Elanco New Practice Program order and will not be eligible for free goods.
- The Elanco New Practice Program order must be placed within 180 days of practice opening.
- Required minimum purchase of $5,000 at list price; no maximum limit for purchased goods.
- Elanco will match free goods to purchased goods, with the following limits – Category 1: Match free goods to purchased goods; max of 2 free cartons per SKU, Category 2: Match free goods to purchased goods; max of $2,500 in free goods (mix/match), Category 3: Match free goods to purchased goods; max of 500 free doses (mix/match).
- Any purchased goods shipped by Elanco will have payment terms of net due 30 days.
- Return of product purchased in association with the New Practice Program are subject to Elanco's approval.
- Elanco, at its sole discretion, reserves the right to modify or terminate this offer at any time.

Elanco™

Elanco™

advantage multi™ for dogs

(imidacloprid+moxidectin)
Topical Solution

Once-a-month topical solution for the prevention of heartworm disease, the treatment of circulating microfilariae, kills adult fleas, is indicated for the treatment of flea infestations, the treatment and control of sarcoptic mange, as well as the treatment and control of intestinal parasite infections in dogs and puppies that are at least 7 weeks of age and that weigh at least 3 lbs.

WARNING
- **DO NOT ADMINISTER THIS PRODUCT ORALLY**
- **For the first 30 minutes after application ensure that dogs cannot lick the product from application sites on themselves or other treated animals.**
- **Children should not come in contact with application sites for two (2) hours after application.**

(See Contraindications, Warnings, Human Warnings, and Adverse Reactions, for more information)

CAUTION:
Federal Law restricts this drug to use by or on the order of a licensed veterinarian.

DESCRIPTION:
Advantage Multi for Dogs (10 % imidacloprid + 2.5 % moxidectin) is a colorless to yellow ready-to-use solution packaged in single dose applicator tubes for topical treatment of dogs. The formulation and dosage schedule are designed to provide a minimum of 4.5 mg/lb (10 mg/kg) imidacloprid and 1.1 mg/lb (2.5 mg/kg) moxidectin based on body weight.

Imidacloprid is a chloronicotinyl nitroguanidine insecticide. The chemical name for imidacloprid is 1-[(6-Chloro-3-pyridinyl)methyl]-N-nitro-2-imidazolidinimine. Moxidectin is a semisynthetic macrocyclic lactone endectocide derived from the actinomycete *Streptomycetes cyaneogriseus noncyanogenus*. The chemical name for moxidectin is [6R, 23E, 25S(E)]-5-O- Demethyl-28-deoxy-25-(1,3-dimethyl-1-butenyl)-6,28-epoxy-23-(methoxyimino) milbemycin B.

INDICATIONS:
Advantage Multi for Dogs is indicated for the prevention of heartworm disease caused by *Dirofilaria immitis* and the treatment of *Dirofilaria immitis* circulating microfilariae in heartworm-positive dogs. *Advantage Multi for Dogs* kills adult fleas and is indicated for the treatment of flea infestations (*Ctenocephalides felis*). *Advantage Multi for Dogs* is indicated for the treatment and control of sarcoptic mange caused by *Sarcoptes scabiei* var. *canis*. *Advantage Multi for Dogs* is also indicated for the treatment and control of the following intestinal parasites:

Intestinal Parasite		Intestinal Stage		
		Adult	Immature Adult	Fourth Stage Larvae
Hookworm Species	*Ancylostoma caninum*	X	X	X
	Uncinaria stenocephala	X	X	X
Roundworm Species	*Toxocara canis*	X		X
	Toxascaris leonina	X		
Whipworm	*Trichuris vulpis*	X		

DOSAGE AND ADMINISTRATION:
The recommended minimum dose is 4.5 mg/lb (10 mg/kg) imidacloprid and 1.1 mg/lb (2.5 mg/kg) moxidectin, once a month, by topical administration.

Do not apply to irritated skin.

1. Remove one dose applicator tube from the package. As specified in the following table, administer the entire contents of the *Advantage Multi for Dogs* tube that correctly corresponds with the body weight of the dog.

Dog (lbs.)	Advantage Multi For Dogs	Volume (mL)	Imidacloprid (mg)	Moxidectin (mg)
3–9	*Advantage Multi 9*	0.4	40	10
9.1–20	*Advantage Multi 20*	1.0	100	25
20.1–55	*Advantage Multi 55*	2.5	250	62.5
55.1–88	*Advantage Multi 88*	4.0	400	100
88.1–110*	*Advantage Multi 110*	5.0	500	125

* Dogs over 110 lbs. should be treated with the appropriate combination of *Advantage Multi for Dogs* tubes.

2. While holding the tube in an upright position, remove the cap from the tube.
3. Turn the cap over and push the other end of cap onto the tip of the tube.
4. Twist the cap to break the seal and then remove cap from the tube.





5. The dog should be standing for application. Part the hair on the back of the dog between the shoulder blades until the skin is visible. For dogs weighing 20 lbs. or less, place the tip of the tube on the skin and apply the entire contents directly on the exposed skin at one spot between the shoulder blades. For dogs weighing more than 20 lbs., place the tip of the tube on the skin and apply the entire contents directly on the exposed skin at 3 or 4 spots on the top of the backline from the base of the neck to the upper back in an area inaccessible to licking. Do not apply an amount of solution at any one location that could run off the side of the dog.

Do not let this product get in your dog's mouth or eyes. **Do not allow the dog to lick any of the application sites for 30 minutes.** In households with multiple pets, keep each treated dog separated from other treated dogs and other pets for 30 minutes after application to prevent licking the application sites.

(See WARNINGS.) Contact with eyes can lead to eye irritation and corneal ulceration. If contact with eyes occurs, hold the dog's eyelids open, flush thoroughly with water, and contact your veterinarian.

Stiff hair, a damp appearance of the hair, pink skin, or a slight powdery residue may be observed at the application site on some animals. This is temporary and does not affect the safety and effectiveness of the product.

Shampooing 90 minutes after treatment does not reduce the effectiveness of *Advantage Multi for Dogs* in the prevention of heartworm disease. Shampooing or water immersion 4 days after treatment will not reduce the effectiveness of *Advantage Multi for Dogs* in the treatment of flea infestations. However, shampooing as often as once weekly may reduce the effectiveness of the product against fleas.

Heartworm Prevention: For prevention of heartworm disease, *Advantage Multi for Dogs* should be administered at one-month intervals. *Advantage Multi for Dogs* may be administered year-round or at a minimum should start one month before the first expected exposure to mosquitoes and should continue at monthly intervals until one month after the last exposure to mosquitoes. If a dose is missed and a 30-day interval between doses is exceeded, administer *Advantage Multi for Dogs* immediately and resume the monthly dosing schedule. When replacing another heartworm preventative product in a heartworm prevention program, the first treatment with *Advantage Multi for Dogs* should be given within one month of the last dose of the former medication.

Treatment of Circulating Microfilaria: For the treatment of circulating *D. immitis* microfilaria in heartworm-positive dogs, *Advantage Multi for Dogs* should be administered at one-month intervals. Treatment with an approved adulticide therapy is recommended because *Advantage Multi for Dogs* is not effective for the treatment of adult *D. immitis*.
(See PRECAUTIONS.)

Flea Treatment: For the treatment of flea infestations, *Advantage Multi for Dogs* should be administered at one-month intervals. If the dog is already infested with fleas when the first dose of *Advantage Multi for Dogs* is administered, adult fleas on the dog will be killed. However, reinfestation from the emergence of pre-existing pupae in the environment may continue to occur for six weeks or longer after treatment is initiated. Dogs treated with imidacloprid, including those with pre-existing flea allergy dermatitis have shown clinical improvement as a direct result of elimination of fleas from the dog.

Treatment and Control of Intestinal Nematode Infections: For the treatment and control of intestinal hookworm infections caused by *Ancylostoma caninum* and *Uncinaria stenocephala* (adults, immature adults and fourth stage larvae) and roundworm infections caused by *Toxocara canis* (adults and fourth stage larvae), and *Toxascaris leonina* (adults), and whipworm infections caused by *Trichuris vulpis* (adults), *Advantage Multi for Dogs* should be administered once as a single topical dose.

Treatment and Control of Sarcoptic Mange: For the treatment and control of sarcoptic mange caused by *Sarcoptes scabiei* var. *canis*, *Advantage Multi for Dogs* should be administered as a single topical dose. A second monthly dose may be administered if necessary.

CONTRAINDICATIONS:
Do not administer this product orally. (See WARNINGS.)
Do not use this product (containing 2.5 % moxidectin) on cats.

WARNINGS
For the first 30 minutes after application:
Ensure that dogs cannot lick the product from application sites on themselves or other treated dogs, and
Separate treated dogs from one another and from other pets to reduce the risk of accidental ingestion.
Ingestion of this product by dogs may cause serious adverse reactions including depression, salivation, dilated pupils, incoordination, panting, and generalized muscle tremors.
In avermectin sensitive dogs,[a] the signs may be more severe and may include coma and death.[b]

[a] Some dogs are more sensitive to avermectins due to a mutation in the MDR1 gene. Dogs with this mutation may develop signs of severe avermectin toxicity if they ingest this product. The most common breeds associated with this mutation include Collies and Collie crosses.

[b] Although there is no specific antagonist for avermectin toxicity, even severely affected dogs have completely recovered from avermectin toxicity with intensive veterinary supportive care.

HUMAN WARNINGS:

Not for human use. Keep out of the reach of children.
Children should not come in contact with application sites for two (2) hours after application.

Causes eye irritation. Harmful if swallowed. Do not get in eyes or on clothing. Avoid contact with skin. Exposure to the product has been reported to cause headache; dizziness; and redness, burning, tingling, or numbness of the skin. **Wash hands thoroughly with soap and warm water after handling.**

If contact with eyes occurs, hold eyelids open and flush with copious amounts of water for 15 minutes. If eye irritation develops or persists, contact a physician. If swallowed, call poison control center or physician immediately for treatment advice. Have person sip a glass of water if able to swallow. Do not induce vomiting unless told to do so by the poison control center or physician. People with known hypersensitivity to benzyl alcohol, imidacloprid or moxidectin should administer the product with caution. In case of allergic reaction, contact a physician. If contact with skin or clothing occurs, take off contaminated clothing. Wash skin immediately with plenty of soap and water. Call a poison control center or physician for treatment advice.

The Safety Data Sheet (SDS) provides additional occupational safety information. For product questions, to report adverse reactions, or for a copy of the Safety Data Sheet (SDS), call Elanco Product & Veterinary Support at 888-545-5973.

PRECAUTIONS:

Do not dispense dose applicator tubes without complete safety and administration information.

Use with caution in sick, debilitated, or underweight animals. The safety of *Advantage Multi for Dogs* has not been established in breeding, pregnant, or lactating dogs. The safe use of *Advantage Multi for Dogs* has not been established in puppies and dogs less than 7 weeks of age or less than 3 lbs. body weight.

Prior to administration of *Advantage Multi for Dogs*, dogs should be tested for existing heartworm infection. At the discretion of the veterinarian, infected dogs should be treated with an adulticide to remove adult heartworms. The safety of *Advantage Multi for Dogs* has not been evaluated when administered on the same day as an adulticide. *Advantage Multi for Dogs* is not effective against adult *D. immitis*. Although the number of circulating microfilariae is substantially reduced in most dogs following treatment with *Advantage Multi for Dogs*, the microfilaria count in some heartworm-positive dogs may increase or remain unchanged following treatment with *Advantage Multi for Dogs* alone or in a dosing regimen with melarsomine dihydrochloride.
(See ADVERSE REACTIONS and ANIMAL SAFETY – Safety Study in Heartworm-Positive Dogs.)

Advantage Multi for Dogs has not been evaluated in heartworm-positive dogs with Class 4 heartworm disease.

ADVERSE REACTIONS:

Heartworm-Negative Dogs

Field Studies: Following treatment with *Advantage Multi for Dogs* or an active control, dog owners reported the following post-treatment reactions:

OBSERVATION	Advantage Multi n = 128	Active Control n = 68
Pruritus	19 dogs (14.8%)	7 dogs (10.3%)
Residue	9 dogs (7.0%)	5 dogs (7.4%)
Medicinal Odor	5 dogs (3.9%)	None observed
Lethargy	1 dog (0.8%)	1 dog (1.5%)
Inappetence	1 dog (0.8%)	1 dog (1.5%)
Hyperactivity	1 dog (0.8%)	None observed

During a field study using 61 dogs with pre-existing flea allergy dermatitis, one (1.6 %) dog experienced localized pruritus immediately after imidacloprid application, and one investigator noted hyperkeratosis at the application site of one dog (1.6 %).

In a field safety and effectiveness study, *Advantage Multi for Dogs* was administered to 92 client-owned dogs with sarcoptic mange. The dogs ranged in age from 2 months to 12.5 years and ranged in weight from 3 to 231.5 pounds. Adverse reactions in dogs treated with *Advantage Multi for Dogs* included hematochezia, diarrhea, vomiting, lethargy, inappetence, and pyoderma.

Laboratory Effectiveness Studies: One dog in a laboratory effectiveness study experienced weakness, depression, and unsteadiness between 6 and 9 days after application with *Advantage Multi for Dogs*. The signs resolved without intervention by day 10 post-application. The signs in this dog may have been related to peak serum levels of moxidectin, which vary between dogs, and occur between 1 and 21 days after application of *Advantage Multi for Dogs*.

The following clinical observations also occurred in laboratory effectiveness studies following application with *Advantage Multi for Dogs* and may be directly attributed to the drug or may be secondary to the intestinal parasite burden or other underlying conditions in the dogs: diarrhea, bloody stools, vomiting, anorexia, lethargy, coughing, ocular discharge and nasal discharge. Observations at the application sites included damp, stiff or greasy hair, the appearance of a white deposit on the hair, and mild erythema, which resolved without treatment within 2 to 48 hours.

Heartworm-Positive Dogs

Field Study: A 56-day field safety study was conducted in 214 *D. immitis* heartworm and microfilaria positive dogs with Class 1, 2 or 3 heartworm disease. All dogs received *Advantage Multi for Dogs* on Study Days 0 and 28; 108 dogs also received melarsomine dihydrochloride on Study Days – 14, 14, and 15. All dogs were hospitalized for a minimum of 12 hours following each treatment. Effectiveness against circulating *D. immitis* microfilariae was > 90 % at five of six sites; however, one site had an effectiveness of 73.3 %. The microfilaria count in some heartworm-positive dogs increased or remained unchanged following treatment with *Advantage Multi for Dogs* alone or in a dosing regimen with melarsomine dihydrochloride.

Following treatment with *Advantage Multi for Dogs* alone or in a dosing regimen with melarsomine dihydrochloride, the following adverse reactions were observed:

Adverse Reaction	Dogs Treated with Advantage Multi for Dogs Only n = 106	Dogs Treated with Advantage Multi for Dogs + Melarsomine n = 108
Cough	24 (22.6%)	25 (23.1%)
Lethargy	14 (13.2%)	42 (38.9%)
Vomiting	11 (10.4%)	18 (16.7%)
Diarrhea, including hemorrhagic	10 (9.4%)	22 (20.4%)
Inappetence	7 (6.6%)	19 (17.6%)
Dyspnea	6 (5.7%)	10 (9.3%)
Tachypnea	1 (< 1%)	7 (6.5%)
Pulmonary Hemorrhage	0	1 (< 1%)
Death	0	3 (2.8%)

Three dogs treated with *Advantage Multi for Dogs* in a dosing regimen with melarsomine dihydrochloride died of pulmonary embolism from dead and dying heartworms. One dog, treated with *Advantage Multi for Dogs* and melarsomine dihydrochloride, experienced pulmonary hemorrhage and responded to supportive medical treatment. Following the first treatment with *Advantage Multi for Dogs* alone, two dogs experienced adverse reactions (coughing, vomiting, and dyspnea) that required hospitalization. In both groups, there were more adverse reactions to *Advantage Multi for Dogs* following the first treatment than the second treatment.

To report a suspected adverse reaction, call 888-545-5973.

Post-Approval Experience (2022)

The following adverse events are based on post-approval adverse drug experience reporting for *Advantage Multi for Dogs*. Not all adverse events are reported to FDA CVM. It is not always possible to reliably estimate the adverse event frequency or establish a causal relationship to product exposure using this data.

The following adverse events reported in dogs are listed in decreasing order of reporting frequency: depression/lethargy, pruritus, vomiting, diarrhea, anorexia, application site reactions (alopecia, pruritus, erythema, and lesions, including blisters), hyperactivity, ataxia, trembling, seizures, panting, hypersalivation, anaphylaxis/anaphylactic reactions (hives, facial swelling, edema of the head), and corneal ulceration.

Serious reactions, including neurologic signs and death have been reported when cats have been exposed (orally and topically) to this product.

In humans, nausea, numbness or tingling of the mouth/lips and throat, ocular and dermal irritation, pruritus, headache, vomiting, diarrhea, depression and dyspnea have been reported following exposure to this product.

Contact Information:

For product questions, to report adverse drug experiences, or for a copy of the Safety Data Sheet (SDS), call Elanco Product & Veterinary Support at 888-545-5973.

For additional information about reporting adverse drug experiences for animal drugs, contact FDA at 1-888-FDA-VETS or http://www.fda.gov/reportanimalae.

ANIMAL SAFETY:

Heartworm-Negative Dogs

Field Study: In a controlled, double-masked, field safety study, *Advantage Multi for Dogs* was administered to 128 dogs of various breeds, 3 months to 15 years of age, weighing 4 to 157 pounds. *Advantage Multi for Dogs* was used safely in dogs concomitantly receiving ACE inhibitors, anticonvulsants, antihistamines, antimicrobials, chondroprotectants, corticosteroids, immunotherapeutics, MAO inhibitors, NSAIDs, ophthalmic medications, sympathomimetics, synthetic estrogens, thyroid hormones, and urinary acidifiers. Owners reported the following signs in their dogs after application of *Advantage Multi for Dogs:* pruritus, flaky/greasy residue at the treatment site, medicinal odor, lethargy, inappetence, and hyperactivity.
(See ADVERSE REACTIONS.)

Safety Study in Puppies: *Advantage Multi for Dogs* was applied topically at 1, 3 and 5X the recommended dose to 7-week-old Beagle puppies once every 2 weeks for 6 treatments on days 0, 14, 28, 42, 56, and 70. Loose stools and diarrhea were observed in all groups, including the controls, throughout the study. Vomiting was seen in one puppy from the 1X treatment group (day 57), in two puppies from the 3X treatment group (days 1 and 79), and in one puppy from the 5X treatment group (day 1). Two puppies each in the 1X, 3X, and 5X groups had decreased appetites within 24 hours post-dosing. One puppy in the 1X treatment group had pruritus for one hour following the fifth treatment. A puppy from the 5X treatment group displayed rapid, difficult breathing from 4 to 8 hours following the second treatment.

Dermal Dose Tolerance Study: *Advantage Multi for Dogs* was administered topically to 8-month-old Beagle dogs at 10X the recommended dose once. One dog showed signs of treatment site irritation after application. Two dogs vomited, one at 6 hours and one at 6 days post-treatment. Increased RBC, hemoglobin, activated partial thromboplastin, and direct bilirubin were observed in the treated group. Dogs in the treated group did not gain as much weight as the control group.

Oral Safety Study in Beagles: *Advantage Multi for Dogs* was administered once orally at the recommended topical dose to 12 dogs. Six dogs vomited within 1 hour of receiving the test article, 2 of these dogs vomited again at 2 hours, and 1 dog vomited again up to 18 hours post-dosing. One dog exhibited shaking (nervousness) 1 hour post-dosing. Another dog exhibited abnormal neurological signs (circling, ataxia, generalized muscle tremors, and dilated pupils with a slow pupillary light response) starting at 4 hours post-dosing through 18 hours post-dosing. Without treatment, this dog was neurologically normal at 24 hours and had a normal appetite by 48 hours post-dosing.
(See CONTRAINDICATIONS.)

Dermal Safety Study in Ivermectin-Sensitive Collies: *Advantage Multi for Dogs* was administered topically at 3 and 5X the recommended dose every 28 days for 3 treatments to Collies which had been prescreened for avermectin sensitivity. No clinical abnormalities were observed.

Oral Safety Study in Ivermectin-Sensitive Collies: *Advantage Multi for Dogs* was administered orally to 5 pre-screened ivermectin-sensitive Collies. The Collies were asymptomatic after ingesting 10 % of the minimum labeled dose. At 40 % of the minimum recommended topical dose, 4 of the dogs experienced neurological signs indicative of avermectin toxicity including depression, ataxia, mydriasis, salivation, muscle fasciculation, and coma, and were euthanized.
(See CONTRAINDICATIONS.)

Heartworm-Positive Dogs

Laboratory Safety Study in Heartworm-Positive Dogs: *Advantage Multi for Dogs* was administered topically at 1 and 5X the recommended dose every 14 days for 3 treatments to dogs with adult heartworm infections and circulating microfilaria. At 5X, one dog was observed vomiting three hours after the second treatment. Hypersensitivity reactions were not seen in the 5X treatment group. Microfilaria counts decreased with treatment.

STORAGE INFORMATION:

Store at temperatures between 4 °C (39 °F) and 25 °C (77 °F), avoiding excess heat or cold.

HOW SUPPLIED:

Applications Per Package
6 x 0.4 mL tubes
6 x 1.0 mL tubes
6 x 2.5 mL tubes
6 x 4.0 mL tubes
6 x 5.0 mL tubes

Revised: January 2023

Approved by FDA under NADA # 141-251

Made in Germany

Manufactured for:
Elanco US Inc
Greenfield, IN 46140 U.S.A.

Bexacat™
(bexagliflozin tablets)

15 mg flavored tablets
For oral use in cats only
Sodium-glucose cotransporter 2 (SGLT2) inhibitor

CAUTION
Federal law restricts this drug to use by or on the order of a licensed veterinarian.

WARNING: DIABETIC KETOACIDOSIS/EUGLYCEMIC DIABETIC KETOACIDOSIS
- **Cats treated with Bexacat may be at an increased risk of diabetic ketoacidosis or euglycemic diabetic ketoacidosis (see Adverse Reactions). As diabetic ketoacidosis and euglycemic diabetic ketoacidosis in cats treated with Bexacat may result in death, development of these conditions should be treated promptly, including insulin administration and discontinuation of Bexacat (see Monitoring).**
- **Due to the risk of developing diabetic ketoacidosis or euglycemic diabetic ketoacidosis, do not use Bexacat in cats with diabetes mellitus who have previously been treated with insulin, who are receiving insulin, or in cats with insulin-dependent diabetes mellitus (see Contraindications).**
- **Bexacat should not be initiated in cats with anorexia, dehydration or lethargy at the time of diagnosis of diabetes mellitus or without appropriate screening tests (see Animal Safety Warnings).**

DESCRIPTION
Bexacat (bexagliflozin tablets) are flavored pentagonal, 10 mm, speckled white, brown, or tan biconvex with a characteristic odor. The empirical formula is $C_{24}H_{29}ClO_7$ and the molecular weight is 464.94 g/mol. The chemical name is (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-(2-cyclopropoxyethoxy)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol.
The chemical structure of bexagliflozin is:



INDICATION
Bexacat is indicated to improve glycemic control in otherwise healthy cats with diabetes mellitus not previously treated with insulin.

DOSAGE AND ADMINISTRATION
Always provide the Client Information Sheet with the prescription.

Dosing Instructions
Administer one tablet by mouth to cats weighing 6.6 lbs (3.0 kg) or greater once daily, at approximately the same time each day, with or without food, and regardless of blood glucose level.

Monitoring
- Sudden onset of hyporexia/anorexia, lethargy, dehydration, or weight loss in cats receiving Bexacat should prompt immediate discontinuation of Bexacat and assessment for diabetic ketoacidosis, regardless of blood glucose level.
- During treatment with Bexacat, blood glucose, fructosamine, serum β-hydroxybutyrate (BHBA), serum feline pancreas-specific lipase (fPL), liver parameters, serum cholesterol and triglycerides; and body weight and clinical signs should be routinely monitored.
  - Increasing or persistently elevated feline pancreas-specific lipase or liver parameters should prompt further evaluation for pancreatitis and/or hepatic disease and consideration for discontinuing Bexacat.
  - BHBA is the predominate ketoacid in diabetic ketoacidosis. Bexacat should be discontinued if a notable reduction in BHBA is not observed after initiation of Bexacat, or if BHBA persistently rises after an initial reduction.
  - Cats with increasing or persistently elevated cholesterol and triglyceride levels may be at an increased risk for developing diabetic ketoacidosis or euglycemic diabetic ketoacidosis.
  - Bexacat should be discontinued if poor glycemic control, as described below, develops.
- During the first 8 weeks after initiation of Bexacat, assessment of glycemic control and clinical improvement should be evaluated.
  - A physical examination, an 8-hour blood glucose curve, serum fructosamine and body weight should be assessed at 2, 4 and 8 weeks.
  - Cats demonstrating poor glycemic control, including weight loss, an average blood glucose concentration from an 8-hour blood glucose curve ≥ 250 mg/dL, and/or a fructosamine indicating poor glycemic control should be closely monitored.
  - Bexacat should be discontinued, and initiation of insulin considered in cats demonstrating poor glycemic control, as described above, at 8 weeks.
- Cats may present with diabetic ketoacidosis and a normal blood glucose concentration (euglycemic diabetic ketoacidosis). Delay in recognition and treatment of diabetic ketoacidosis and euglycemic diabetic ketoacidosis may result in increased morbidity and mortality.
- Development of diabetic ketoacidosis and euglycemic diabetic ketoacidosis requires the following actions:
  - Discontinuation of Bexacat
  - Prompt initiation of insulin therapy
  - Administration of dextrose or other carbohydrate source, regardless of blood glucose concentration
  - Appropriate nutritional support should be promptly initiated to prevent or treat hepatic lipidosis.

For more information refer to **CONTRAINDICATIONS** and **WARNINGS.**

CONTRAINDICATIONS
- Do not use Bexacat in cats with diabetes mellitus who have previously been treated with insulin, who are receiving insulin, or in cats with insulin-dependent diabetes mellitus. The use of Bexacat in cats with insulin-dependent diabetes mellitus, or the withdrawal of insulin and initiation of Bexacat, is associated with an increased risk of diabetic ketoacidosis or euglycemic diabetic ketoacidosis and death.
- Due to risk of severe adverse reactions, do not use Bexacat in cats with evidence of hepatic disease or reduced renal function.

WARNINGS
User Safety Warnings
Not for use in humans. Keep out of reach of children. Consult a physician in case of accidental ingestion by humans.

Animal Safety Warnings
- Bexacat should not be initiated in cats with:
  - Anorexia, dehydration, or lethargy at the time of diagnosis of diabetes mellitus, as it may indicate the presence of other concurrent disease and increase the risk of diabetic ketoacidosis.
  - An fPL level > 5.3 mcg/L, diagnostic imaging consistent with pancreatitis, a history of pancreatitis, or current clinical signs suggestive of pancreatitis.
  - Laboratory values consistent with diabetic ketoacidosis, including elevated urine or serum ketones, and metabolic acidosis (high anion gap, or decreased bicarbonate, pH, or partial pressure carbon dioxide [$PaCO_2$] levels).
  - A BHBA > 37 mg/dL, or if BHBA is > 25 mg/dL and the cat has a history of renal disease or metabolic acidosis.
- Persistent plasma bexagliflozin concentrations and reduced clearance of Bexacat, represented as the presence of plasma half-lives in excess of 24 hours, may result in prolonged clinical effects such as glucosuria and/or euglycemia despite discontinuation of Bexacat in some cats with hepatic disease and/or reduced renal function, including cats with clinically undetectable disease at the time of Bexacat initiation. Reduced clearance of Bexacat may contribute to persistent glucosuria, resulting in an osmotic diuresis and dehydration that requires appropriate hydration support. These cats may require hospitalization, which may be protracted, for sequalae such as diabetic ketoacidosis, euglycemic diabetic ketoacidosis, or hepatic lipidosis.
- Cats should be screened for urinary tract infections and treated, if indicated, when initiating Bexacat. Treatment with Bexacat may increase the risk for urinary tract infections (see **Adverse Reactions**). Cats treated with Bexacat should be monitored for urinary tract infections and treated promptly. Consider discontinuation of Bexacat in cats with recurrent urinary tract infections.
- Bexacat may cause increased serum calcium concentrations. Bexacat should be discontinued in cats with persistent increases in serum total calcium or ionized calcium because of increased risk of forming calcium containing uroliths (see **Adverse Reactions**).
- Long term use of Bexacat may increase the risk of urothelial carcinoma (see **Adverse Reactions**).
- Keep Bexacat in a secure location out of reach of dogs, cats, and other animals to prevent accidental ingestion or overdose.

PRECAUTIONS
- Bexacat should be discontinued in cats who develop diarrhea unresponsive to conventional therapy.
- Consider temporary discontinuation of Bexacat in cats during times of decreased caloric intake, such as surgery or decreased appetite, as administration of Bexacat in these cats may increase the risk of diabetic ketoacidosis or hepatic lipidosis.
- The osmotic diuretic effects of Bexacat may contribute to inappropriate urination in some cats (see **Adverse Reactions**).
- Polyphagia as a compensatory response to caloric wasting from glucosuria may persist in up to 80% of cats, despite evidence of adequate glycemic control, and may lead to progressive weight gain.
- Approximately 20-30% of cats may have persistent polyuria and/or polydipsia secondary to Bexacat-induced osmotic diuresis and may be a risk factor for dehydration-associated diabetic ketoacidosis.
- The concurrent use of volume depleting drugs in cats treated with Bexacat has not been evaluated.
- The safety of Bexacat in breeding, pregnant, and lactating cats has not been evaluated.

ADVERSE REACTIONS
Field Study
Eighty-four cats with newly diagnosed diabetes mellitus were enrolled in a 180-day multicenter field effectiveness and safety study. Safety data were evaluated in 84 cats treated with at least one dose of Bexacat. All cats received one tablet, once daily, regardless of body weight or blood glucose level. Seventy-two of the 84 enrolled cats completed the study. The most common adverse reactions included elevated blood urea nitrogen (BUN), vomiting, elevated urine specific gravity (USG), elevated serum fPL, diarrhea, anorexia, lethargy, and dehydration. The adverse reactions seen during the field study are summarized in Table 1 below.

Table 1. Adverse Reactions (n=84)

Adverse Reaction	Number (%)
Elevated BUN*	46 (54.8)
Vomiting	42 (50.0)
Elevated USG†	33 (39.3)
Elevated fPL‡	33 (39.3)
Diarrhea	32 (38.1)
Anorexia	31 (37.0)
Lethargy	17 (20.2)
Dehydration	16 (19.0)
Elevated symmetrical dimethylarginine (SDMA)	13 (15.5)
Weight loss	13 (15.5)
Urinary tract infection	12 (14.3)

Adverse Reaction	Number (%)
Elevated ALT and/or AST§	11 (13.1)
Hypercalcemia	8 (9.5)
Behavioral changes**	6 (7.1)
Proteinuria	5 (6.0)
Elevated creatinine	4 (4.8)
Elevated creatine kinase	4 (4.8)
Inappropriate urination	4 (4.8)
Death	3 (3.6)
Diabetic ketoacidosis	3 (3.6)
Pancreatitis	3 (3.6)
Euglycemic diabetic ketoacidosis	2 (2.4)
Hepatic lipidosis	2 (2.4)
Elevated alkaline phosphatase	2 (2.4)
Elevated total bilirubin	2 (2.4)
Constipation	2 (2.4)

* Most cats had elevations < 1.5 times the upper limit of normal (ULN).
† Elevations were predominantly attributable to dehydration and/or glucosuria.
‡ Most cats had one or more isolated elevations, followed by a return to previous values.
§ Of nine cats with elevations ≥ 1.5X ULN, 2 cats developed diabetic ketoacidosis and were transitioned to insulin. One cat developed diabetic ketoacidosis and hepatic lipidosis resulting in death (euthanasia). One cat developed anemia, progressive weight loss and fPL elevations resulting in death.
** Observations included hiding, agitation, aggression, vocalization, and anxious behavior.

Nine serious adverse reactions associated with Bexacat administration occurred during the study, including three cats who died or were euthanized. Of the three cats who died or were euthanized, two cats became clinically ill within 5 doses of Bexacat administration (range 3 to 5 doses). One cat with euglycemic diabetic ketoacidosis and hepatic lipidosis was euthanized due to further deterioration of its clinical condition, despite supportive treatment. One cat demonstrating anorexia, lethargy, dehydration, azotemia, and hypokalemia was euthanized without supportive treatment. One cat, who demonstrated a lack of effectiveness, anemia and hepatic lipidosis died on Day 77 despite supportive treatment and additional diagnostics. Six of the nine cats had serious adverse reactions that did not result in death or euthanasia. Five cats were treated for their clinical conditions and transitioned to insulin. Serious adverse reactions in these cats were associated with the following conditions (number of cats): euglycemic diabetic ketoacidosis (1); lack of effectiveness, diabetic ketoacidosis, elevated liver parameters (1); diabetic ketoacidosis (1); diabetic ketoacidosis and pyelonephritis (1); and lack of effectiveness, weight loss, dehydration (1). One cat with constipation and pancreatitis received supportive treatment and remained on Bexacat (bexagliflozin tablets).

Pilot Field Study

Eighty-nine cats with newly diagnosed diabetes mellitus were enrolled in a 56-day multicenter pilot field effectiveness and safety study, with continued use for up to 180 days. All cats received one tablet, once daily, regardless of body weight or blood glucose level. Safety data were evaluated for all 89 cats treated with at least one dose of bexagliflozin. The most common adverse reactions included elevated blood urea nitrogen (BUN), elevated urine specific gravity (USG), elevated serum feline pancreas-specific lipase, vomiting, diarrhea/loose stool, hyporexia/anorexia, lethargy, elevated serum alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST), and urinary tract infections. The adverse reactions seen in the pilot study are summarized in Table 2 below.

Table 2. Adverse Reactions (n=89)

Adverse Reaction	Number (%)
Elevated BUN*	51 (57.3)
Elevated USG†	43 (48.3)
Elevated fPL‡	39 (43.8)
Vomiting	39 (43.8)
Diarrhea/Loose Stool	29 (32.6)
Hyporexia/Anorexia	28 (31.4)
Lethargy	16 (18.0)
Elevated ALT and/or AST§	13 (14.6)
Urinary tract infection	13 (14.6)
Dehydration	10 (11.2)
Elevated symmetrical dimethylarginine (SDMA)	10 (11.2)
Behavioral changes**	9 (10.1)
Ketosis/Ketonuria	8 (9.0)
Weight loss	8 (9.0)
Proteinuria	8 (9.0)
Pancreatitis	7 (7.9)
Death	6 (6.7)
Anemia	6 (6.7)
Hepatopathy	6 (6.7)
Hypercalcemia	4 (4.5)
Elevated creatine kinase	4 (4.5)
Inappropriate urination	4 (4.5)
Peritonitis	3 (3.4)
Constipation	3 (3.4)
Elevated creatinine	2 (2.2)
Euglycemic diabetic ketoacidosis	2 (2.2)
Diabetic ketoacidosis	2 (2.2)
Hemolytic anemia	2 (2.2)
Elevated total bilirubin	2 (2.2)

* Most cats had elevations ≤ 1.5X upper limit of normal (ULN).
† Elevations were predominantly attributable to dehydration and/or glucosuria.
‡ Most cats had one or more isolated elevations, followed by a return to previous values.
§ Most elevations were ≤ 2X ULN. One cat had marked ALT and AST (9X and 6X upper limit of normal, respectively) elevations on Day 28. Following discontinuation of bexagliflozin, the liver enzymes decreased within 24 hours and returned to within reference range in 10 days.
** Observations included hiding, hyperactivity, vocalization, and abnormal behavior.

Twenty cats (22%) had at least one blood glucose value < 65 mg/dL recorded during 8-hour blood glucose curves. No clinical signs of hypoglycemia were observed and bexagliflozin dosing was not adjusted in any cat due to documented hypoglycemia. Nine serious adverse reactions associated with bexagliflozin administration occurred during the study, including six cats who died or were euthanized. Of the six cats who died or were euthanized, five became clinically ill within receiving 5 doses of bexagliflozin (range 1 to 5 doses). Four of the cats were euthanized due to further deterioration of their clinical condition despite supportive treatment. One cat died despite supportive treatment. Deaths were associated with the following conditions (number of cats): necrotizing pancreatitis and pancreatic abscess (1), pancreatitis and hepatic lipidosis (1), euglycemic diabetic ketoacidosis and severe hepatic lipidosis (1), pancreatitis and hepatic abscesses (1), diabetic ketoacidosis (1), and persistent polyuria and polydipsia and quality of life concerns (1).

Three of nine serious adverse reactions that did not result in death or euthanasia included the following (number of cats): acute hepatocellular injury (1), immune-mediated hemolytic anemia (1), and euglycemic diabetic ketoacidosis with concurrent pancreatitis and hepatopathy (1). Two cats with serious adverse reactions demonstrated persistent bexagliflozin blood plasma levels and elimination half-lives after discontinuation of bexagliflozin. One cat with renal and liver values within the reference range at screening was euthanized due to a continued decline in clinical condition despite treatment for euglycemic diabetic ketoacidosis and severe hepatic lipidosis. The second cat, noted to have IRIS (International Renal Interest Society) stage II renal disease and liver values within the reference range at screening, recovered following treatment for marked liver enzyme elevations above the reference range on Day 28.

Extended Use Field Study

One hundred twenty-five cats with diabetes mellitus that had previously completed a bexagliflozin field study were enrolled in a multicenter extended use field study. Cats were enrolled in the study for a range of 7 to 1064 days, with a mean of 329 days. Safety data were evaluated for all 125 cats treated with at least one dose of Bexacat (bexagliflozin tablets). All cats received one tablet, once daily, regardless of body weight or blood glucose level. Forty-nine of the 125 enrolled cats were withdrawn from the study due to adverse reactions, serious adverse reactions, death/euthanasia, lack of effectiveness, suspected diabetic remission, withdrawal of owner consent, or lost to follow up. The most common adverse reactions were similar to those noted in the previous field studies and included elevated USG (35.2%), vomiting (27.2%), elevated fPL (26.4%), anorexia (24.0%), diarrhea (22.4%), urinary tract infections (17.6%), lethargy (16.8%), and death (16.0%).

Twenty serious adverse reactions associated with Bexacat administration occurred during the study, all resulting in death or euthanasia. Clinical signs of hypoglycemia were observed in two of these cats. Deaths were associated with the following conditions (number of cats), with some cats experiencing multiple comorbidities (necropsy was not granted in all cases): euglycemic diabetic ketoacidosis (8); diabetic ketoacidosis (4); hepatic lipidosis (5); pancreatic necrosis/peripancreatic fat saponification (3); urothelial carcinoma (2); hypercalcemia, recurrent calcium containing cystic calculi (1); lack of effectiveness, weight loss, anorexia (1); lethargy, weight loss, pallor (1); chronic renal disease, glomerulonephritis (1); chronic enteropathy (1); hypoglycemia, possible pancreatitis (1).

CONTACT INFORMATION

To report suspected adverse events, for technical assistance, or to obtain a copy of the Safety Data Sheet (SDS), contact Elanco US Inc at 1-888-545-5973.

For additional information about reporting adverse drug experiences for animal drugs, contact FDA at 1-888-FDA-VETS or http://www.fda.gov/reportanimalae.

INFORMATION FOR CAT OWNERS

Owners should be given the Client Information Sheet to read before Bexacat is administered. Owners should be advised to discontinue Bexacat and contact a veterinarian immediately if their cat develops anorexia, lethargy, vomiting, diarrhea, or weakness.

CLINICAL PHARMACOLOGY

Mechanism of Action

Bexagliflozin is an inhibitor of sodium-glucose cotransporter 2 (SGLT2), the renal transporter responsible for reabsorption of glucose from the glomerular filtrate back into the circulation. By inhibiting SGLT2, bexagliflozin reduces renal reabsorption of filtered glucose and lowers the renal threshold for glucose, thereby increasing urinary glucose excretion.

Pharmacokinetics

In a laboratory pilot study conducted to determine the prandial state of maximum exposure, systemic exposure for bexagliflozin was greater in the fasted state than in the fed state by 82% for the mean maximum observed plasma concentration (C_{max}), and by 54% for the mean area under the plasma concentration versus time curve (AUC) from dosing (time 0) to the last quantifiable concentration ($AUC_{0\text{-last}}$), respectively.

In a well-controlled margin of safety study (see **Target Animal Safety**), mean C_{max} was approximately dose-proportional over a dosage range of 5 mg/kg (1X) to 25 mg/kg (5X). Mean AUC from time 0 to 24 hours exposure was approximately dose-proportional over a dosage range of 5 to 15 mg/kg, but more than dose-proportional at 15 to 25 mg/kg. An increase in exposure ($AUC_{0\text{-}24}$ and C_{max}), was observed in female cats compared to male cats on all evaluation days. Median time to reach peak plasma concentration (T_{max}) was approximately 0.5 hours (range 0.5 to 2 hours) and mean half-life ($T_{1/2}$) was approximately 5 hours across all dose groups. There was no accumulation of bexagliflozin following daily dosing of 5, 15, and 25 mg/kg in healthy non-diabetic cats. However, field studies showed that some diabetic cats had persistent bexagliflozin blood levels after discontinuation of the drug, which may be related to a decrease in liver function in some cats (see **Animal Safety Warnings**).

EFFECTIVENESS

Field Study

Eighty-four cats diagnosed with diabetes mellitus were enrolled in a 180-day multicenter field effectiveness and safety study. Enrolled cats included purebreds and mixed breeds, ranging in age from 3 to 19 years, and weighing between 7.3 to 24.3 lbs (3.3 to 11.3 kg). Cats received one tablet, once daily, regardless of body weight or blood glucose level. Treatment success was defined as improvement in at least one blood glucose variable (blood glucose curve mean or fructosamine) and improvement in at least one clinical sign of diabetes mellitus (polyuria, polydipsia, polyphagia, or body weight [weight gain or no weight loss]).

Of 77 cats included in the effectiveness-evaluable population:

- 64 cats (83.1%) were considered a treatment success on Day 56.
- The lower bound two-sided 90% confidence interval was 74.5%. Effectiveness was demonstrated if the lower bound of the confidence interval was > 66%.
- Mean blood glucose curve mean decreased from 284 mg/dL on Day 0 to 143 mg/dL on Day 56.
- Mean fructosamine levels decreased from 544 µmol/L prior to Day 0 to 295 µmol/L on Day 56.
- Improvements in the clinical signs of polyuria, polydipsia, polyphagia, and body weight on Day 56 were observed in 53 (68.8%), 57 (74.0%), 44 (57.1%), and 42 (54.6%) cats, respectively.
- 66 cats (85.7%) completed the 180-day study.

Pilot Field Study

Eighty-nine cats diagnosed with diabetes mellitus were enrolled in a 56-day, multicenter pilot field effectiveness and safety study with continued use for up to 180 days. Enrolled cats included purebreds and mixed breeds, ranging in age from 3 to 17 years and weighing 6.4 to 22.9 lbs (2.9 to 10.4 kg). Cats received one tablet, once daily, regardless of weight. Treatment success was defined as improvement in at least one blood glucose variable (blood glucose curve mean or fructosamine) and improvement in at least one clinical sign of diabetes mellitus (polyuria, polydipsia, polyphagia, or body weight [weight gain or no weight loss]). Of the 72 cats included in the effectiveness-evaluable population, 58 (80.6%) were considered treatment successes on Day 56.

TARGET ANIMAL SAFETY

In a well-controlled laboratory margin of safety study, Bexacat was administered orally to 28 fasted, healthy, lean, intact adult cats at doses of at least 1X (8 cats), 3X (8 cats), and 5X (12 cats) the maximum exposure dose (5 mg/kg) once daily for 26 weeks. The contro group (8 cats) was sham dosed. The maximum exposure dose (5 mg/kg) was based on the assessment that the minimum weight of an eligible cat with diabetes mellitus is approximat 3 kg. Polyuria, glucosuria (with a corresponding increase in food consumption), loose stools diarrhea, and ketonuria were reported more frequently in cats that received Bexacat than in control cats. There were drug-related clinically insignificant increases in calcium, magnesiur and cholesterol levels, and decreases in creatinine and amylase levels, and blood pressure and heart rate values. Gross necropsy demonstrated treatment-related observations of mild, diffuse zonal patterns in the liver. One cat with the observed zonal pattern had mild elevatior of alanine aminotransferase (ALT) and aspartate aminotransferase (AST), and a histopatholo observation of minimal, multifocal necrosis in the liver. The histopathological finding did not correspond to the zonal patterns observed grossly. There were no clinically relevant, drug-related effects on hematology and coagulation parameters and organ weight values.

STORAGE CONDITIONS Bexacat should be stored at room temperature 68 to 77 ˚F (20 to 25 °C).

HOW SUPPLIED

Flavored tablet each containing 15 mg bexagliflozin; 30 or 90 tablets per bottle.

Approved by FDA under NADA # 141-566
Manufactured for: Elanco US Inc, Greenfield, IN 46140

September 2022

Credelio Quattro™

(lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets)

Flavored Chewable Tablets
For oral use in dogs only

CAUTION
Federal law restricts this drug to use by or on the order of a licensed veterinarian.

DESCRIPTION
Credelio Quattro (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) are flavored chewable tablets available in five sizes for oral administration to dogs and puppies according to their weight. Each chewable is formulated to provide minimum doses of 9 mg/lb (20 mg/kg) lotilaner, 0.009 mg/lb (0.02 mg/kg) moxidectin, 2.28 mg/lb (5 mg/kg) praziquantel, and 2.28 mg/lb (5 mg/kg) pyrantel (as pamoate salt).

Lotilaner is a member of the isoxazoline class of parasiticides and the chemical name is 5-[(5S)-4,5-dihydro-5-(3,4,5-trichlorophenyl)-5-(trifluoromethyl)-3-isoxazolyl]-3-methyl-N-[2-oxo-2-[(2,2,2-trifluoroethyl) amino]ethyl]- 2-thiophenecarboxamide.

Moxidectin is a semisynthetic macrocyclic lactone derived from the actinomycete *Streptomycetes cyaneogriseus noncyanogenus.* The chemical name for moxidectin is [6R,23E,25S(E)]-5-O- demethyl-28-deoxy-25-(1,3-dimethyl-1-butenyl)- 6,28-epoxy-23-(methoxyimino) milbemycin B.

Praziquantel is an isoquinolone anthelmintic with the chemical name 2-(cyclohexylcarbonyl)-1,2,3,6,7,-11b-hexahydro-4H-pyrazino [2,1- a]isoquinolin-4-one.

Pyrantel is a member of the tetrahydropyrimidine family of compounds. Its chemical name is (E)- 1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl) vinyl] pyrimidine 4, 4' methylenebis [3-hydroxy-2-naphthoate](1:1).

INDICATIONS
Credelio Quattro is indicated for the prevention of heartworm disease caused by *Dirofilaria immitis* and for the treatment and control of roundworm (immature adult and adult *Toxocara canis* and adult *Toxascaris leonina*), hookworm (adult *Uncinaria stenocephala*), and tapeworm (*Dipylidium caninum, Taenia pisiformis,* and *Echinococcus granulosus*) infections. Credelio Quattro kills adult fleas and is indicated for the treatment and prevention of flea infestations (*Ctenocephalides felis*) and the treatment and control of tick infestations [*Amblyomma americanum* (lone star tick), *Dermacentor variabilis* (American dog tick), *Ixodes scapularis* (black-legged tick), and *Rhipicephalus sanguineus* (brown dog tick)] for one month in dogs and puppies 8 weeks of age and older, and weighing 3.3 pounds or greater.

DOSAGE AND ADMINISTRATION
Credelio Quattro is given orally once a month, at the minimum dosage of 9 mg/lb (20 mg/kg) lotilaner, 0.009 mg/lb (0.02 mg/kg) moxidectin, 2.28 mg/lb (5 mg/kg) praziquantel, and 2.28 mg/lb (5 mg/kg) pyrantel (as pamoate salt). Credelio Quattro must be administered with food (see **Clinical Pharmacology**). Care should be taken to ensure that the dog consumes the complete dose and that part of the dose is not lost or refused. If vomiting occurs within an hour after administration, readminister a new dose of Credelio Quattro. If a dose is missed, give Credelio Quattro immediately and resume a monthly dosing schedule.

Dosing Schedule:

Body Weight (lbs)	Tablets to Administer	Lotilaner per Tablet (mg)	Moxidectin per Tablet (mg)	Praziquantel per Tablet (mg)	Pyrantel* per Tablet (mg)
3.3 – 6	1	56.25	0.056	14.25	14.25
6.1 – 12	1	112.5	0.113	28.5	28.5
12.1 – 25	1	225	0.225	57	57
25.1 – 50	1	450	0.45	114	114
50.1 – 100	1	900	0.9	228	228
> 100	Administer the appropriate combination of tablets				

*As pamoate salt

Heartworm Prevention
Credelio Quattro should be administered year-round at monthly intervals or at least within 1 month of the animal's first seasonal exposure to mosquitoes and continuing until at least 1 month after the dog's last seasonal exposure. If a dose is missed, give Credelio Quattro immediately and resume monthly dosing. When replacing a monthly heartworm preventive product, Credelio Quattro should be given within 1 month of the last dose of the former medication.

Intestinal Nematode and Cestode Treatment and Control
Credelio Quattro should be administered as a single dose for the treatment of roundworm, hookworm, and tapeworm infections.
Monthly use of Credelio Quattro will control any subsequent infections. Dogs may be exposed to and can become infected with gastrointestinal worms throughout the year, regardless of season or climate. Clients should be advised of appropriate measures to prevent reinfection of their dog with intestinal parasites.

Flea Treatment and Prevention
Treatment with Credelio Quattro should be administered year-round at monthly intervals or started at least 1 month before fleas become active. To minimize the likelihood of flea re-infestation, it is important to treat all dogs and cats within a household with a flea control product.

Tick Treatment and Control
Treatment with Credelio Quattro can begin at any time of the year. Credelio Quattro should be administered year-round at monthly intervals or started at least 1 month before ticks become active.

CONTRAINDICATIONS
There are no known contraindications for the use of Credelio Quattro.

WARNINGS
Not for use in humans. Keep this and all drugs out of reach of children. Wash hands after handling. If accidentally ingested, seek medical attention immediately.

Keep Credelio Quattro in a secure location out of reach of dogs, cats, and other animals to prevent accidental ingestion or overdose.

PRECAUTIONS
Lotilaner, one of the ingredients in Credelio Quattro, is a member of the isoxazoline class. This class has been associated with neurologic adverse reactions including tremors, ataxia, and seizures. Seizures have been reported in dogs receiving isoxazoline class drugs, even in dogs without a history of seizures. Use with caution in dogs with a history of seizures or neurologic disorders.

Prior to administration of Credelio Quattro, dogs should be tested for existing heartworm infections. At the discretion of the veterinarian, infected dogs should be treated with an adulticide to remove adult heartworms. Credelio Quattro is not effective against adult *D. immitis*.

The safe use of Credelio Quattro in breeding, pregnant, or lactating dogs has not been evaluated.

ADVERSE REACTIONS
In a field safety and effectiveness study, Credelio Quattro was administered to dogs for the prevention of heartworm disease.
The study included a total of 372 dogs treated once monthly for up to 11 treatments (191 treated with Credelio Quattro and 181 treated with an active control). Over the 330-day study period, all observations of potential adverse reactions were recorded.

Adverse reactions seen during the field study are summarized in the table below.

Dogs with Adverse Reactions in the Field Study

Clinical Sign	Credelio Quattro N=191 Number (Percentage)	Active Control N=181 Number (Percentage)
Diarrhea, with or without blood*	21 (11%)	15 (8.3%)
Vomiting	18 (9.4%)	8 (4.4%)
Lethargy	12 (6.3%)	1 (0.6%)
Anorexia	11 (5.8%)	5 (2.8%)
Dermatitis	10 (5.2%)	8 (4.4%)
Weight Loss	6 (3.1%)	3 (1.7%)
Pruritus (itching)	3 (1.6%)	1 (0.6%)
Alopecia (hair loss)	2 (1.0%)	4 (2.2%)
Seizure	1 (0.5%)	4 (2.2%)
Ataxia	1 (0.5%)	1 (0.6%)
Nystagmus	1 (0.5%)	0 (0.0%)
Anisocoria	1 (0.5%)	1 (0.6%)

*Four dogs administered Credelio Quattro and five dogs administered the active control had bloody diarrhea.

One geriatric dog receiving Credelio Quattro experienced two episodes of vomiting, ataxia, and nystagmus, 11 days apart, with the first episode occurring two days after the eighth dose. The dog recovered within 24 hours after the first episode and 1 hour after the second episode and completed the study. One dog receiving Credelio Quattro was observed by the investigator to have anisocoria during scheduled physical examinations one month after the ninth dose and one month after the eleventh dose.

In a U.S. field study, 165 dogs received a combination of lotilaner, moxidectin, and praziquantel, three of the active ingredients at the same doses as in Credelio Quattro, monthly for up to 11 months. Two dogs with no history of seizures experienced seizures during the study. One of the dogs developed cluster seizures and was removed from the study. Ataxia was also observed in one other dog three days after the first dose.

In a U.S. field study, one dog administered lotilaner alone, a component of Credelio Quattro, was observed with intermittent head tremors within 1.5 hours of administration of vaccines, an ear cleaning performed by the owner, and its first dose of lotilaner.
The head tremors resolved within 24 hours without treatment. The owner elected to withdraw the dog from the study.

In an Australian field study, one dog with a history of seizures experienced seizure activity (tremors and glazed eyes) six days after receiving lotilaner alone.

The dog recovered without treatment and completed the study. In a U.S. field study, two dogs with a history of seizures received lotilaner alone and experienced no seizures throughout the study.

CONTACT INFORMATION

For a copy of the Safety Data Sheet (SDS) or to report suspected adverse drug events, contact Elanco US Inc. at 1-888-545-5973.

For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or http://www.fda.gov/reportanimalae.

INFORMATION FOR ANIMAL OWNER

Echinococcus granulosus is a tapeworm found in wild canids and domestic dogs. *E. granulosus* can infect humans and cause serious disease (hydatid disease). Owners of dogs living in areas where *E. granulosus* is endemic should be instructed on how to minimize their risk of exposure to this parasite, as well as their dog's risk of exposure. Although Credelio Quattro was 100% effective in laboratory studies in dogs against *E. granulosus*, no studies have been conducted to show that the use of this product will decrease the incidence of hydatid disease in humans.

CLINICAL PHARMACOLOGY

Mechanism of Action

Credelio Quattro contains four active pharmaceutical ingredients, lotilaner, moxidectin, praziquantel, and pyrantel (as pamoate salt).

Lotilaner is an ectoparasiticide belonging to the isoxazoline group. Lotilaner inhibits insect and acarine gamma-aminobutyric acid (GABA)-gated chloride channels. This inhibition blocks the transfer of chloride ions across cell membranes, which results in uncontrolled neuromuscular activity leading to death of insects and acarines. The selective toxicity of lotilaner between insects and acarines and mammals may be inferred by the differential sensitivity of the insects and acarines' GABA receptors versus mammalian GABA receptors.

Moxidectin is an endectocide in the macrocyclic lactone class. Moxidectin acts by interfering with the chloride channel-mediated neurotransmission in the parasite. This results in paralysis and death of the parasite.

Praziquantel's mode of action is not precisely known, but treated tapeworms undergo muscular paralysis accompanied by a rapid influx of calcium ions and the disruption of the tegument.

Pyrantel is a nematocide belonging to the tetrahydropyrimidine class. Pyrantel acts as a depolarizing, neuromuscular-blocking agent in susceptible parasites, causing paralysis and death or expulsion of the parasite.

Pharmacokinetics

Due to reduced drug bioavailability of lotilaner in the fasted state, Credelio Quattro must be administered with a meal or within 30 minutes after feeding.

Following a single oral administration of Credelio Quattro at the minimum labeled dose in the fed state or a single intravenous administration of 5 mg lotilaner, 0.005 mg moxidectin, 1.25 mg praziquantel, and 1.25 mg pyrantel per kg body weight to Beagle dogs (1.5 to 2.5 years old), the mean oral bioavailability for lotilaner, praziquantel, and pyrantel was 93%, 41%, and 31%, respectively. Bioavailability for moxidectin is not reported due to insufficient data to adequately describe the elimination phase following intravenous administration. For Credelio Quattro, the area under the curve from time of dosing to the time of the last measurable concentration (AUC_{last}) was 5970, 1.75, 1.54, and 0.857 mg*h/L for lotilaner, moxidectin, praziquantel, and pyrantel, respectively. Peak concentrations (C_{max}) of 9070, 15.3, 390, and 122 ng/mL were reached (T_{max}) 10, 4.5, 0.75, and 2.5 h after dosing for lotilaner, moxidectin, praziquantel, and pyrantel, respectively. Mean plasma elimination half-lives were 806, 634, 3.64, and 4.87 h for lotilaner, moxidectin, praziquantel, and pyrantel, respectively.

Following nine oral administrations of Credelio Quattro at 1X, 3X, and 5X the maximum labeled dose of 40 mg/kg lotilaner, 0.04 mg/kg moxidectin, 10 mg/kg praziquantel, and 10 mg/kg pyrantel, every 28 days in 8-week-old Beagle dogs, moxidectin and lotilaner area under the curve from time of dosing to the time of the last measurable concentration (AUC_{last}) increased approximately in a less than proportional manner, whereas praziquantel AUC_{last} increased approximately in a more than proportional manner from 1X to 5X after most study doses. Pyrantel AUC_{last} increased approximately in a proportional manner from 1X to 5X observed after first, sixth, and last doses. Within the 1X group, accumulation was observed between Days 0 and 224 with geometric mean accumulation ratios for AUC_{last} of 6.2 and 7.9 for lotilaner and moxidectin, respectively. Concentrations of praziquantel and pyrantel prior to each dose were below the limit of quantification.

EFFECTIVENESS

Heartworm Prevention

In two well-controlled laboratory studies, a single oral dose of Credelio Quattro was 100% effective in preventing the development of adult *D. immitis* in dogs inoculated with infective larvae 30 days before administration.

In a well-controlled U.S. field study consisting of 156 dogs administered Credelio Quattro and 149 administered an active control for 11 consecutive months, no dogs treated with Credelio Quattro tested positive for heartworm disease. All dogs treated with Credelio Quattro were negative for *D. immitis* antigen and blood microfilariae at study completion on Day 330.

Intestinal Nematode and Cestode Treatment and Control

In well-controlled laboratory studies, a single dose of Credelio Quattro was ≥ 97.0% effective against immature adult and adult *Toxocara canis*, adult *Toxascaris leonina,* and adult *Uncinaria stenocephala* infections.

In well-controlled laboratory studies, a single dose of Credelio Quattro was 100% effective against *Echinococcus granulosus*.

In separate well-controlled laboratory studies, praziquantel alone was 100% effective against *Echinococcus granulosus, Dipylidium caninum,* and *Taenia pisiformis*.

Flea Treatment and Prevention

In a well-controlled laboratory study, Credelio Quattro was 100% effective against adult fleas 24 hours after administration or infestation for 36 days. In a separate laboratory study, lotilaner alone began to kill fleas 4 hours after administration or infestation, with greater than 99% of fleas killed within 8 hours after administration or infestation for 35 days.

In a well-controlled U.S. field study conducted in households with existing flea infestations of varying severity, flea reductions of 99.5% to 100% were observed over the course of three monthly treatments with lotilaner alone. Dogs with signs of flea allergy dermatitis showed improvement in erythema, papules, scaling, alopecia, dermatitis/pyodermatitis, and pruritus as a direct result of eliminating fleas.

Tick Treatment and Control

In well-controlled laboratory studies, Credelio Quattro was ≥ 97.1% effective against *Rhipicephalus sanguineus* ticks 48 hours after administration or infestation for 32 days. In well-controlled laboratory studies, lotilaner alone was > 97% effective against *Amblyomma americanum*, *Dermacentor variabilis*, *Ixodes scapularis,* and *Rhipicephalus sanguineus* ticks 48 hours after administration or infestation for 30 days. In a well-controlled European laboratory study, lotilaner alone started killing *Ixodes ricinus* ticks within 4 hours after administration.

Palatability: In the U.S. field study, which included 552 doses administered to 191 dogs, dogs voluntarily consumed 59.8% of Credelio Quattro doses from an empty bowl, on the floor, or when offered by hand, and an additional 28.4% of doses when offered with food. The administration of 11.8% of doses required placement of the chewable tablet in the back of the dog's mouth. All doses were administered within 30 minutes of a meal.

TARGET ANIMAL SAFETY

Margin of Safety

Credelio Quattro was administered orally at 0X, 1X, 3X, and 5X the maximum labeled doses at 28-day intervals for nine treatments to 32 healthy, 8-week-old Beagle puppies. Dogs in the control group received placebo. Credelio Quattro-related clinical chemistry findings included increased bile acids in two of the 3X dogs. Minimal mononuclear cell infiltration of the liver was noted microscopically in five control dogs, two 1X dogs, three 3X dogs, and five 5X dogs. One control dog, one 1X dog, two 3X dogs, and none of the 5X dogs also had minimal extramedullary hematopoiesis. Credelio Quattro-related clinical observations included a dose-dependent increase in discolored feces, diarrhea, and vomiting. All dogs recovered without treatment. Hypersalivation associated with vomiting on the day of dosing occurred in two of the 5X dogs.

Avermectin Sensitive Collie Safety

Credelio Quattro was administered orally at 0X, 1X, 2X, and 5X the maximum labeled dose at 28-day intervals for three treatments to 32 healthy, avermectin sensitive Collie dogs. Dogs in the control group received a vehicle control. One dog in each of the control, 2X, and 5X groups had transient mild depression. Salivation and vomiting was observed in a dose-dependent manner in the 1X, 2X, and 5X groups. Diarrhea, with or without blood, was observed in all groups, including controls, and resolved without treatment.

Heartworm Positive Safety

Credelio Quattro was administered orally at 0X, 1X, and 3X the maximum labeled dose at 28-day intervals for three treatments to 24 healthy, Beagle dogs with patent adult heartworm infections and circulating microfilariae. Dogs in the control group received placebo. Diarrhea and/or vomiting occurred in all dogs in the 3X group at various times up to 12 hours post-dose. Diarrhea occurred in fewer dogs in the 1X and control groups. All dogs experiencing post-dose gastrointestinal issues recovered without treatment. Hypersensitivity reactions (e.g., anaphylaxis, shock, collapse, respiratory distress, or depression) were not observed in any dog.

Field Safety

In a well-controlled field study, Credelio Quattro was used concurrently with other medications such as vaccines, antimicrobials, anthelmintics, antiemetics, steroidal and nonsteroidal anti-inflammatory drugs (NSAIDs), anesthetics, and analgesics. No adverse reactions were associated with the concurrent use of Credelio Quattro and other medications.

HOW SUPPLIED

Credelio Quattro (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) is available in five strengths of flavored chewable tablets formulated according to the weight of the dog (see **Dosage and Administration**). Each chewable tablet size is available in packages of 1, 6, or 12 tablets.

STORAGE INFORMATION

Store at 15-25°C (59-77°F). Excursions permitted between 5 and 40°C (41 and 104°F).

Approved by FDA under NADA # 141-581

Manufactured for: Elanco US Inc, Greenfield, IN 46140

June 2024

Zenrelia™
(ilunocitinib tablets)

Immunomodulator
For oral use in dogs only

CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

WARNING: VACCINE-INDUCED DISEASE AND INADEQUATE IMMUNE RESPONSE TO VACCINES

Based on results of the vaccine response study, dogs receiving Zenrelia are at risk of fatal vaccine-induced disease from modified live virus vaccines and inadequate immune response to any vaccine. Discontinue Zenrelia for at least 28 days to 3 months prior to vaccination and withhold Zenrelia for at least 28 days after vaccination (see Warnings and Target Animal Safety).

DESCRIPTION
Zenrelia is a synthetic Janus kinase (JAK) inhibitor. Zenrelia is a member of the pyrimidines class of JAK inhibitors and its chemical name is 2-[1-cyclopropylsulfonyl-3-[4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile.

INDICATIONS
Zenrelia is indicated for control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.

DOSAGE AND ADMINISTRATION
The dose of Zenrelia (ilunocitinib tablets) is 0.27 to 0.36 mg ilunocitinib/lb (0.6 to 0.8 mg ilunocitinib/kg) body weight, administered orally, once daily, with or without food.

Dosing Chart

Weight Range (in lb)	Weight Range (in kg)	Number of Tablets to be Administered			
		4.8 mg tablets	6.4 mg tablets	8.5 mg tablets	15 mg tablets
6.6 – 8.8	3.0 - 4.0	0.5			
8.9 – 11.8	4.1 – 5.3		0.5		
11.9 – 14.3	5.4 – 6.5			0.5	
14.4 – 17.7	6.6 – 8.0	1			
17.8 – 23.6	8.1 – 10.6		1		
23.7 – 31.1	10.7 – 14.1			1	
31.2 – 35.4	14.2 – 16.0		1.5		
35.5 – 43.1	16.1 – 19.5			1.5	
43.2 – 55.0	19.6 – 24.9				1
55.1 – 62.5	25.0 – 28.3			2	
62.6 – 83.3	28.4 – 37.4				1.5
83.4 – 110.0	37.5 – 49.9				2
110.1 – 137.5	50.0 – 62.4				2.5
137.6 – 166.0	62.5 – 74.9				3
≥ 166.1	≥ 75	Administer the appropriate combination of tablet strengths			

WARNINGS
User Safety Warnings
Not for use in humans. Keep this drug out of the reach of children. Wash hands immediately after handling tablets. In case of accidental ingestion, seek medical attention immediately.

Animal Safety Warnings
Due to the risk of fatal vaccine-induced disease from modified live virus vaccines and inadequate immune response to any vaccine, including rabies vaccines, do not administer vaccines to a dog receiving Zenrelia. Discontinue Zenrelia for at least 28 days to 3 months prior to vaccination and withhold Zenrelia for at least 28 days after vaccination (see **Target Animal Safety**).

Dogs should be monitored for the development of infections because Zenrelia may increase susceptibility to opportunistic infections, including demodicosis, interdigital furunculosis, coccidiosis, and pneumonia, and exacerbation of subclinical or uncomplicated infections (see **Target Animal Safety** and **Adverse Reactions**).

Zenrelia is not for use in dogs with serious infections.

Zenrelia may cause a progressive or persistently decreased hematocrit, hemoglobin, and/or red blood cell count without a corresponding increase in absolute reticulocyte count (see **Target Animal Safety**).

New neoplastic conditions (benign and malignant) were observed in dogs treated with Zenrelia during clinical studies (see **Adverse Reactions**).

Consider the risks and benefits of treatment prior to initiating Zenrelia in dogs with a history of recurrent serious infections or recurrent demodicosis or neoplasia (see **Adverse Reactions** and **Target Animal Safety**).

Zenrelia modulates the immune system.

Zenrelia is not for use in dogs less than 12 months of age (see **Target Animal Safety**).

Keep Zenrelia in a secure location out of reach of dogs, cats, and other animals to prevent accidental ingestion or overdose.

PRECAUTIONS
Dogs should be up to date on vaccinations prior to starting Zenrelia (see **Target Animal Safety**).

The safe use of Zenrelia has not been evaluated in breeding, pregnant, or lactating dogs.

Decreased prostate gland weights in intact male dogs were observed in a laboratory safety study (see **Target Animal Safety**).

The safe use of Zenrelia has not been evaluated in combination with glucocorticoids, cyclosporine, or other systemic immunosuppressive agents.

ADVERSE REACTIONS
Control of Atopic Dermatitis

In a masked field study assessing effectiveness and safety of Zenrelia for the control of atopic dermatitis in dogs, 181 Zenrelia-treated dogs and 87 placebo-treated dogs diagnosed with atopic dermatitis were evaluated for safety up to 112 days. By Day 112, 66.7% of placebo-treated dogs and 22.1% of Zenrelia-treated dogs exited the study. Adverse reactions seen during the field study are summarized in Table 1 below.

Table 1. Adverse Reactions through Day 112

Adverse Reaction	Zenrelia N = 181 Number of Dogs (%)	Placebo N = 87 Number of Dogs (%)
Vomiting or nausea	40 (22.1 %)	14 (16.1 %)
Diarrhea	36 (19.9 %)	9 (10.3 %)
Lethargy	22 (12.2 %)	9 (10.3 %)
Otitis externa	19 (10.5 %)	20 (23.0 %)
Anorexia	17 (9.4 %)	7 (8.0 %)
Dermal growth (e.g., cyst, papilloma)	16 (8.8 %)	4 (4.6 %)
Epiphora or ocular discharge	14 (7.7 %)	1 (1.1 %)
Coughing or wheezing, including respiratory infections	12 (6.6 %)	2 (2.3 %)
Bacterial skin infection	10 (5.5 %)	9 (10.3 %)
Elevated liver enzyme(s)	10 (5.5 %)	2 (2.3 %)
Urinary tract infection	10 (5.5 %)	2 (2.3 %)
Upset stomach, including flatulence and abdominal pain	10 (5.5 %)	0
Leukopenia	9 (4.9 %)	1 (1.1 %)
Sneezing	8 (4.4 %)	1 (1.1 %)
Lipoma	7 (3.9 %)	1 (1.1 %)
Weight gain	7 (3.9 %)	0
Increased water intake	4 (2.2 %)	2 (2.3 %)
Gingivitis (occurrence or worsening)	4 (2.2 %)	0
Blood in stool	4 (2.2 %)	0
Elevated total bilirubin	4 (2.2 %)	0
Elevated triglyceride	4 (2.2 %)	0
Histiocytoma	3 (1.7 %)	0
Increased appetite	3 (1.7 %)	0
Fungal skin infection	3 (1.7 %)	2 (2.3 %)
Weight loss	2 (1.1 %)	1 (1.1 %)
Metastatic neoplasia (i.e., hemangiosarcoma)	1 (0.6 %)	0
Systemic fungal infection	1 (0.6 %)	0
Mast cell tumor	1 (0.6 %)	0

N = number of dogs

Abnormal hematology results likely related to Zenrelia treatment included thrombocytopenia, leukopenia, neutropenia, lymphopenia, eosinopenia, monocytopenia, and decreased red blood cell count.

Abnormal serum chemistry results likely related to Zenrelia treatment included increased hepatobiliary parameters (alanine transaminase, aspartate aminotransferase, alkaline phosphatase, gamma-glutamyl transferase, and total bilirubin), increased blood urea nitrogen (concurrently with an increase in creatinine for one dog), hypertriglyceridemia, hypercholesterolemia, hypoalbuminemia (without a concurrent hyperglobulinemia), and hypoglobulinemia (with or without a decrease in total protein).

Twelve Zenrelia-treated dogs withdrew from the study early due to an adverse reaction, nine of which were considered likely related to Zenrelia treatment. These reactions included repeated episodes of vomiting, leukopenia, neutropenia, worsening of pre-existing lymphocytosis, enlargement of a non-resolving histiocytoma, eyelid mass with bacterial blepharitis, otitis interna with vestibular disease, urinary tract infection, and upper respiratory infection. Five placebo dogs withdrew from the study early due to an adverse reaction (i.e., lethargy, worsening of pre-existing lymphocytosis, occurrence of nystagmus, skin infection, and teat infection).

One Zenrelia-treated dog was diagnosed with splenic and liver masses on Day 112. Histopathologic diagnosis after euthanasia one month later confirmed metastatic splenic and hepatic hemangiosarcoma. Another Zenrelia-treated dog experienced traumatic tendonitis and a puncture wound four days prior to study completion, which progressed to a serious infection. The owner elected amputation after study completion. A third Zenrelia-treated dog experienced a moderate neutropenia on Day 28 associated with a pre-existing subclinical urinary tract infection (UTI) that had progressed into a clinical UTI. The neutrophil count normalized seven days later while still receiving Zenrelia, prior to exiting the study to receive antibiotics.

Control of Pruritus Associated with Allergic Dermatitis

In a masked field study assessing effectiveness and safety of Zenrelia for the control of pruritus associated with allergic dermatitis in dogs, 206 Zenrelia-treated dogs and 100 placebo-treated dogs diagnosed with allergic dermatitis were evaluated for safety up to 112 days. By Day 112, 84% of placebo-treated dogs and 49.5% of Zenrelia-treated dogs exited the study. Adverse reactions seen during the field study are summarized in Table 2 below.

Table 2. Adverse Reactions through Day 112

Adverse Reaction	Zenrelia N = 206 Number of Dogs (%)	Placebo N = 100 Number of Dogs (%)
Vomiting or nausea	32 (15.5%)	11 (11.0 %)
Diarrhea	26 (12.2 %)	5 (5.0 %)
Lethargy	25 (12.1 %)	7 (7.0 %)
Urinary tract infection	13 (6.3 %)	2 (2.0 %)
Anorexia	10 (4.9 %)	3 (3.0 %)
Coughing, wheezing, or difficulty breathing	9 (4.4 %)	0
Elevated liver enzyme(s)	8 (3.9 %)	0
Otitis externa	8 (3.9 %)	5 (5.0 %)
Increased water intake	7 (3.4 %)	2 (2.0 %)
Upset stomach, including flatulence, retching, and abdominal pain	5 (2.4 %)	4 (4.0 %)
Ocular discharge	5 (2.4 %)	1 (1.0 %)
Elevated triglyceride	5 (2.4 %)	0
Dermal or subcutaneous growth (e.g., cyst, nodule)	3 (1.5 %)	2 (2.0 %)
Sneezing	3 (1.5 %)	0
Blood in stool	3 (1.5 %)	0
Increased urination	3 (1.5 %)	0
Bacterial skin infection	2 (1.0 %)	4 (4.0 %)
Weight gain	2 (1.0 %)	0
Neurological disorder (e.g., tremors, ataxia)	2 (1.0 %)	0
Increased appetite	1 (0.5 %)	0
Fungal skin infection	1 (0.5 %)	0
Fever	1 (0.5 %)	0
Hematuria (without urinary tract infection)	1 (0.5 %)	0

N = number of dogs

Abnormal hematology results likely related to Zenrelia treatment included thrombocytosis, leukopenia, neutropenia, eosinopenia, and monocytopenia.

Abnormal serum chemistry results likely related to Zenrelia treatment included increased hepatobiliary parameters (alanine transaminase, aspartate aminotransferase, alkaline phosphatase, gamma-glutamyl transferase, and total bilirubin), increased blood urea nitrogen, increased creatinine, hypertriglyceridemia, hypercholesterolemia, hypoproteinemia, and hypoglobulinemia (with or without a decrease in total protein).

Seven Zenrelia-treated dogs withdrew from the study early due to an adverse reaction, four of which were considered likely related to Zenrelia treatment. These reactions included vomiting, lethargy, soft stool, neutropenia, increased liver enzymes, fever, abdominal discomfort, coughing, and wheezing. Four placebo treated dogs also withdrew from the study early due to an adverse reaction (i.e., splenic hemangiosarcoma, restlessness, abdominal pain, lethargy, and vomiting).

CONTACT INFORMATION

To report suspected adverse events, for technical assistance, or to obtain a copy of the Safety Data Sheet (SDS), contact Elanco US Inc at 1-888-545-5973.

For additional information about reporting adverse drug experiences for animal drugs, contact FDA at 1-888-FDA-VETS or http://www.fda.gov/reportanimalae.

CLINICAL PHARMACOLOGY

Mechanism of Action

Ilunocitinib is a non-selective JAK inhibitor which inhibits the function of a variety of pruritogenic, pro-inflammatory and allergy related cytokines that are dependent upon JAK enzymes. Ilunocitinib has a high potency for JAK1, JAK2, and tyrosine kinase 2 (TYK2) inhibition. Ilunocitinib is not a corticosteroid or an antihistamine.

Pharmacokinetics

Ilunocitinib is rapidly and well absorbed and excreted via the biliary/fecal route after oral administration in dogs. Following a single oral or intravenous administration of ilunocitinib at 0.8 mg/kg, the oral bioavailability based on area under the curve from the time of dosing to the last quantifiable plasma concentration (AUC_{last}) was 80% in the fed state and 60% in the fasted state. The systemic clearance following intravenous administration was 399 mL/hour(h)/kg with a terminal half-life of 3.6 h. The volume of distribution was 1390 mL/kg (n=8). The maximum plasma concentration (C_{max}) and AUC_{last} were 120% and 45% higher, respectively, in the fed state as compared to the fasted state (n=16).

In a laboratory margin of safety study, healthy adult dogs (see **Target Animal Safety**) received daily oral administration of Zenrelia at 0.8 mg/kg, 1.6 mg/kg, 2.4 mg/kg, or 4.0 mg/kg for 182 consecutive days. Dogs were dosed in the fed state, the prandial state of maximum bioavailability. At 0.8 mg/kg, the ilunocitinib mean (coefficient of variation %) C_{max} was 310 ng/mL (20.6%) with a median time to C_{max} of 2 h (range 1 – 2 h), and the AUC_{last} and half-life were 1360 h*ng/mL (25.1%) and 3.3 h (11.9%), respectively. Minimal accumulation was observed between Days 1 and 182 with geometric mean accumulation ratios for C_{max} and AUC_{last} between 1.1 and 1.6. After the first dose, C_{max} increased in a linear but less than proportional manner where a 5-fold increase in dose resulted in a 3.4-fold (90% confidence limit: 2.9 – 4.0) increase in C_{max}. There was a non-linear relationship between dose and AUC_{last} where a 5-fold increase in dose resulted in a 4.2-fold (90% confidence limit: 3.4 – 5.1) increase in AUC_{last}. Pharmacokinetic parameters are presented as geometric means.

EFFECTIVENESS

Control of Atopic Dermatitis:

A masked, placebo-controlled field study was conducted at 25 veterinary clinics in the US and Canada, enrolling 268 client-owned dogs diagnosed with atopic dermatitis and having at least moderate pruritus and mild skin lesions. Dogs were randomized to once daily treatment with Zenrelia at 0.6 – 0.8 mg/kg or placebo, at a ratio of 2:1 respectively. Other medications that could affect the evaluation of effectiveness were not allowed during the study, such as corticosteroids, antihistamines, and cyclosporine. Treatment success for each dog was defined as a ≥ 50% reduction from baseline in owner-assessed pruritus scores on the Pruritus Visual Analog Scale (PVAS) or a ≥ 50% reduction from baseline in veterinarian-assessed skin lesion scores on the Canine Atopic Dermatitis Extent and Severity Index version 4 (CADESI-4) on Day 28. The proportion of dogs in the Zenrelia group that were treatment successes was greater than and significantly different from the placebo group on Day 28 (Table 3, below).

Table 3. Estimated Proportion of Dogs Achieving Treatment Success

Treatment Group	Estimated Proportion of Success*
Zenrelia (N = 172)	0.83
Placebo (N = 77)	0.31†

* Based on back-transformed least squares means.
† Placebo vs. Zenrelia $p < 0.001$
N = Number of dogs

The Zenrelia group had a higher proportion of dogs with a ≥ 50% reduction from baseline in both owner-assessed PVAS and veterinarian-assessed CADESI-4 scores, compared to placebo, at all time points. The mean owner-assessed PVAS and veterinarian-assessed CADESI-4 scores were also lower for the Zenrelia group compared to the placebo group at all time points.

Control of Pruritus Associated with Allergic Dermatitis

A masked, placebo-controlled field study was conducted at 15 veterinary clinics in the US, enrolling 306 client-owned dogs diagnosed with allergic dermatitis and having at least moderate pruritus. The allergic dermatitis was attributed to one or more of the following conditions: atopic dermatitis, contact dermatitis, flea allergy dermatitis, food hypersensitivity, or other. Dogs were randomized to once daily treatment with Zenrelia at 0.6 – 0.8 mg/kg or placebo, at a ratio of 2:1 respectively. Other medications that could affect the evaluation of effectiveness were not allowed during the study, such as corticosteroids, antihistamines, and cyclosporine. Treatment success for each dog was defined as a ≥ 50% reduction from baseline in owner-assessed pruritus scores on the Pruritus Visual Analog Scale (PVAS) on at least 5 out of the first 7 days of treatment. The proportion of dogs in the Zenrelia group that were treatment successes was greater than and significantly different compared to the placebo group on Day 7 (Table 4, below).

Table 4. Estimated Proportion of Dogs Achieving Treatment Success

Treatment Group	Estimated Proportion of Success*
Zenrelia (N = 193)	0.25
Placebo (N = 91)	0.08†

* Based on back-transformed least squares means.
† Placebo vs. Zenrelia $p = 0.006$
N = number of dogs

The Zenrelia group had a higher proportion of dogs with a ≥ 50% reduction from baseline in owner-assessed PVAS, compared to placebo, on Days 2 through 7.
After Day 1, mean owner-assessed PVAS scores were lower in the Zenrelia group (Figure 1, below).

Figure 1. Mean owner-assessed PVAS Scores by Treatment for Days 0-7



Veterinarians used a dermatitis visual analog scale (DVAS) to assess each dog's dermatitis. Veterinarian-assessed DVAS scores were lower for the Zenrelia group compared to the placebo group at all time points through Day 28.

TARGET ANIMAL SAFETY

Margin of Safety Study:

Zenrelia was administered to 40 (8 dogs per group) healthy, 11 to 12-month-old, fed Beagle dogs, once daily at 0X, 1X, 2X, 3X and 5X the maximum exposure dose of 0.8 mg/kg for 6 months. Control dogs were sham-dosed. Zenrelia-related clinical observations included a dose-dependent increase in the frequency and severity of interdigital furunculosis (cysts), with or without discharge on one or more paws, swollen and/or scabbing paws, and paw skin thickening and/or discoloration. Zenrelia-related hemogram findings included a dose-dependent minimal to moderate decrease in hematocrit (HCT), hemoglobin (HGB), and red blood cell (RBC) count without a corresponding increase in absolute reticulocyte count. Other Zenrelia-related findings included a minimal to mild decrease in mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentrations (MCHC), and eosinophil counts. Abnormal clinical pathology observations considered secondary to the interdigital furunculosis, included minimal to moderate increases in fibrinogen concentrations, total protein, C-reactive protein, and globulins, and decreases in albumin, albumin/globulin ratio and calcium levels. There were no Zenrelia-related effects on lymphocytes, monocytes, and basophils. Two dogs in the 5X group had minimally lower myeloid:erythroid ratios consistent with a physiological bone marrow response to the lower red blood cell mass despite no apparent effect on absolute reticulocytes. Zenrelia-related pathology changes included decreased prostate gland weights in the 5X group males and interdigital papillomas and/or dermatitis/furunculosis, predominantly in the 5X group. One dog in the 5X group had enlarged and mildly reactive draining lymph nodes associated with interdigital furunculosis. One dog in the 3X group had a papilloma on each paw with fragments of *Demodex canis*, and a follicular cyst within the markedly inflamed dermis.

Vaccine Response Study:

Zenrelia was administered to 16 (8 dogs per group) healthy, 10-month-old, vaccine naïve Beagle dogs, once daily at 0 and 3X the maximum exposure dose of 0.8 mg/kg for 89 days. Control dogs were placebo dosed. An 84-day recovery period followed in which no drug was administered. Dogs were administered a multivalent modified live virus (MLV) vaccine, including canine adenovirus type-2 (CAV-2), canine parvovirus (CPV), and canine distemper virus (CDV), on Days 28 and 60 and a killed rabies virus (RV) vaccine on Day 60. The primary endpoint was achievement on Day 88 of predefined serum titer thresholds considered adequate for protective immunity. Serum titers were also evaluated 27 days (RV only) and 83 days after discontinuing drug administration (Days 116 and 172, respectively).

On Day 52, one dog administered Zenrelia was euthanized due to lethargy, depression, poor body condition, and weakness. Necropsy revealed findings consistent with a colonic intussusception, potentially related to a clinical *Cystoisospora canis* infection secondary to Zenrelia-induced immunosuppression. On Day 54, another dog administered Zenrelia was euthanized due to lethargy, depression, poor body condition, and weakness. Histopathology evaluation revealed marked necrotizing hepatitis and pancreatitis and evidence of systemic endotoxemia. Prominent intranuclear inclusion bodies were found in the liver and pancreas, consistent with adenoviral infection. The adenoviral hepatitis and pancreatitis were concluded to be vaccine-induced, secondary to Zenrelia-induced immunosuppression.

Clinical signs observed in Zenrelia-treated dogs included poor body condition, pale mucous membranes, lethargy, diarrhea, vomiting, weight loss, decreased appetite, and depression likely due to a clinical *C. canis* infection secondary to Zenrelia-induced immunosuppression in seven of the eight dogs. No dogs in the control group were diagnosed with a *C. canis* infection. One dog in the control group had diarrhea. Zenrelia-related clinical observations also included interdigital cysts, lameness, and thickening and crusting of the ear margins. Clinical pathology findings in Zenrelia-treated dogs included decreases in hematocrit, hemoglobin, and red blood cell counts with a corresponding increase in absolute reticulocyte count, and decreases in total serum protein, albumin, and globulins, likely due to the *C. canis* infection.

On Day 88, all eight control dogs demonstrated an adequate immune response to CAV-2, CPV, CDV, and RV vaccination and all six remaining dogs receiving Zenrelia demonstrated an adequate immune response to CAV-2 and CPV vaccination. Four (of six) Zenrelia-treated dogs failed to demonstrate an adequate immune response to RV vaccination, and one (of six) Zenrelia-treated dogs failed to demonstrate an adequate immune response to CDV vaccination on Day 88.

During the recovery period, on Day 116 (27 days after discontinuing treatment), one (of eight) control dogs and one (of six) Zenrelia-treated dogs failed to demonstrate an adequate immune response to RV vaccination. On Day 172 (83 days after discontinuing treatment), all eight control dogs demonstrated an adequate immune response to CAV-2, CPV, and CDV vaccinations, all six remaining Zenrelia-treated dogs demonstrated an adequate immune response to CAV-2 and CPV vaccination, one (of six) Zenrelia-treated dogs failed to demonstrate an adequate immune response to CDV vaccination, and one (of eight) control dogs and three (of six) Zenrelia-treated dogs failed to demonstrate an adequate immune response to RV vaccination.

Potential recovery from drug-induced immunosuppression 27 days after discontinuing Zenrelia is evidenced by the observed adequate immune response to RV vaccination on Day 116 in three of the four dogs in the Zenrelia group that failed to achieve an adequate RV titer while receiving Zenrelia on Day 88. However, one of these four dogs did not achieve adequate RV titers after Zenrelia was discontinued for 83 days. A 3-month washout period prior to vaccination is supported by the 2024 World Small Animal Veterinary Association and 2023 Center for Disease Control and Prevention vaccination guidelines. The 28-day time period to withhold Zenrelia after vaccination is based on published and unpublished data evaluating the duration of MLV vaccine virus shedding.

Pilot Margin of Safety Study:

A non-final formulation of ilunocitinib (oral suspension) was administered via gavage to 32 (8 dogs per group) healthy, 9-month-old, Beagle dogs, once daily at 0X, 1X, 3X, and 4.5X the maximum exposure dose of 0.8 mg/kg through Day 64. Due to serious adverse reactions in the 3X and 4.5X groups, on Day 65, the 4.5X group was decreased to 2X through Day 185. Control dogs were sham dosed. One dog in the 4.5X group and two dogs in the 3X group were prematurely euthanized (on Days 52, 57, and 134, respectively) due to an acute onset of lethargy, labored breathing, fever, tremors, and pale gums, starting within four hours of dosing via oral gavage. Microscopic pathology findings in the three dogs included necrotizing hemorrhagic pneumonia, considered secondary to ilunocitinib-induced immunosuppression and gavage administration. Two of these three dogs developed severe leukopenia and neutropenia and one dog had severe weight loss in the two weeks prior to euthanasia. Twelve dogs administered ilunocitinib, including the three dogs prematurely euthanized, had a decrease in at least one RBC parameter (HCT, HGB, or RBC count), without a corresponding increase in absolute reticulocyte count, at one or more timepoints during the study. Additional ilunocitinib-related microscopic pathology changes included minimal to mild increased erythropoiesis and pigment in the spleen, minimal to mild pigmented macrophages in the liver, and minimal adipocyte accumulation in the bone marrow.

STORAGE CONDITIONS

Store at room temperature between 15 to 25°C (59 to 77°F), excursions permitted between 5 to 40°C (41 to 104°F).

HOW SUPPLIED

Zenrelia (ilunocitinib tablets) is available in scored tablets in four strengths: 4.8 mg, 6.4 mg, 8.5 mg, and 15 mg. Each tablet strength is available in 10 and 30 count blister packages and 90 count bottles.

Manufactured for Elanco US Inc. Greenfield, IN 46140

Approved by FDA under NADA # 141-585

July 2024
PA104098X

midwest veterinary supply

Approximately 65% of veterinary visits involve wound assessment or care, presenting veterinary teams with the frequent challenge of managing wounds and client expectations.

Reduce stress, increase compliance

Wounds are already stressful and E-collars can cause additional discomfort, fear, and anxiety to the pet. Because of this, E-collar compliance is low, often resulting in additional visits and prolonged healing.

1 Single product solution

While there are a variety of wound products available, they are often expensive and offer limited efficacy, requiring multiple products be used.

Stop the lick

Wounds are often licked, exacerbating the existing condition, or worse, the pet pulls out the sutures, impacting wound progression.

Requires no E-collar

E-collars cause disruptions to a pet's daily life including the ability to eat, play, and maintain basic hygiene. They're often uncomfortable and can lead to unintended pet parent injuries or property damage.

Learn more by visiting keravetbio.com

Complete safety and use information is available on keravetbio.com

Robert Moreau
KeraVet Bio, Director of Sales
C. 336.399.1169
E. rmoreau@keravetbio.com

Promotional Details
No quantity restrictions
No code required
Ongoing

CONGRATULATIONS
on your new clinic opening

LLOYD, Inc. would like to help get you started in the right direction with an in-kind gift of up to $500 in superior quality pharmaceutical and nutritional products.

LLOYD, Inc. will match your purchase with complimentary products up to $500*

BUY 1 GET 1 FREE

Quality. Value. Results.

*Offer valid within 90 days of clinic opening/new ownership transfer.

Offer valid for orders placed through any U.S. veterinary distributor of LLOYD, Inc. products.

No minimum purchase required.

Maximum $500 free goods value.

Free, in kind product match is valid for products purchased on a single distributor invoice only.

Free goods shipped directly from LLOYD, Inc. to your clinic.

Post, fax or email a copy of your completed New Clinic Offer Order Form (reverse) and your associated distributor invoice to LLOYD, Inc. Marketing for prompt processing and delivery (within 2-4 weeks):

LLOYD™

LLOYD, Inc. of Iowa
Attn: Marketing
PO Box 130
Shenandoah, IA 51601
800-831-0004
FAX: 712-246-5245
EMAIL:
marketing@lloydinc.com

NEW CLINIC OFFER ORDER FORM

New Owner Name:

Clinic Name:

Address:

City, State, Zip:

Telephone:

Email:

Distributor:

Are you interested in receiving future educational/ promotional materials from LLOYD, Inc. via email?

YES **NO**

REDEMPTION INSTRUCTIONS:

Return Completed New Clinic Order Form along with your Distributor Invoice to LLOYD, Inc. Marketing by fax, email or post.

FAX: 712-246-5245

EMAIL: marketing@lloydinc.com

POST: LLOYD, Inc. Marketing
PO Box 130
Shenandoah, IA 51601

Pharmaceutical Staples*

Small Animal	Strength/Size	Quantity
Methio-Form® DL-Methionine 500 mg per tablet	50 tablet bottle	
	150 tablet bottle	
	500 tablet bottle	
PrednisTab® Prednisolone USP	20 mg - 500 tablet bottle	
	5 mg - 1,000 tablet bottle	
Thryo-Tabs® Canine 0.1 mg Levothyroxine sodium	120 tablet bottle	
	1,000 tablet bottle	
Thryo-Tabs® Canine 0.2 mg Levothyroxine sodium	120 tablet bottle	
	1,000 tablet bottle	
Thryo-Tabs® Canine 0.3 mg Levothyroxine sodium	120 tablet bottle	
	1,000 tablet bottle	
Thryo-Tabs® Canine 0.4 mg Levothyroxine sodium	120 tablet bottle	
	1,000 tablet bottle	
Thryo-Tabs® Canine 0.5 mg Levothyroxine sodium	120 tablet bottle	
	1,000 tablet bottle	
Thryo-Tabs® Canine 0.6 mg Levothyroxine sodium	120 tablet bottle	
	1,000 tablet bottle	
Thryo-Tabs® Canine 0.7 mg Levothyroxine sodium	120 tablet bottle	
	1,000 tablet bottle	
Thryo-Tabs® Canine 0.8 mg Levothyroxine sodium	120 tablet bottle	
	1,000 tablet bottle	
Thryo-Tabs® Canine 1.0 mg Levothyroxine sodium	120 tablet bottle	
	1,000 tablet bottle	
Large Animal	**Strength/Size**	**Quantity**
Thryo-L® Levothyroxine sodium (powdered)	1 pound bottle	
	10 pound pail	

Nutritional Supplements & Other Necessities

Small Animal	Strength/Size	Quantity
Avi-Con Multi-vitamin nutrition for health and feathering.	50 gram bottle	
Cani-Flex D-Glucosamine HCL for joint health. 500 mg per tablet	60 tablet bottle	
Derma-Form Multi-vitamin, mineral and fatty acid nutrition for skin and coat.	8 fluid ounce bottle	
Felo-Form® Multi vitamin and mineral nutrition for cats.	50 tablet bottle	
Geri-Form Multi-vitamin nutrition for senior health and cognitive function.	50 tablet bottle	
	150 tablet bottle	
Isotone SA Buffered isotonic supplement for optimal fluid absorption.	16 gram packets 24 packets/ carton 6 cartons/case	
Lipo-Form® Multi-vitamin, lipotropic nutrition for fatty liver resolution and weight loss support.	50 tablet bottle	
	500 tablet bottle	
Osteo-Form Calcium:phosporus (1.8:1) nutrition for healthy bone growth.	50 tablet bottle	
	150 tablet bottle	
	500 tablet bottle	
	350 gram (powder) bottle	
Pet-Form® Multi-vitamin, mineral and fatty acid nutrion for the growing years.	50 tablet bottle	
	150 tablet bottle	
	500 tablet bottle	
ToxiBan® Activated charcoal for organic toxin adsorption.	1 pound (granules) bottle	
	5 kg/[11 lb] (granules) pail	
	240 mL (suspension) bottle – with or without sorbitol	
Veta-Lac® Canine Veta-Lac® Feline Canine-specific and feline-specific milk replacers.	400 gram bottle (canine)	
	5 kg/[11 lb] pail (canine)	
	200 gram bottle (feline)	

Large Animal	Strength/Size	Quantity
Bio-Meth Biotin and DL-Methionine nutrition for hoof health and strength.	400 gram bottle	
	2,000 gram bottle	
Biotin-100 Biotion nutrition for hoof health.	5 pound bag	
	20 pound pail	
Bloat-Pac® Emulsion for use in correcting acute frothy bloat (vet-use).	500 mL bottle	
	1 gallon bottle	
Carti-Form HS Glucosamine nutrition for joint health.	640 gram bottle	
Equ-Lin Mentholated liniment for sore muscle relief.	12 fluid ounce bottle	
Equ-Aid® Plus Multi-vitamin and mineral nutrition for performance.	5 pound jar	
	40 pound pail	
Equ-SeE Selenium and Vitamin E nutrition.	1 pound bottle	
	5 pound jar	
Hydra-Lyte® Electrolytes and nutrition to correct dehydration and hypoglycemia.	5.76 ounce packets	
	18 pound pail	
Osteo-Form Powder Calcium:phosporus (1.8:1) nutrition for healthy bone growth.	425 gram bottle	
	25 pound pail	
Rumen-Eze® Emulsion for use in correcting recurrent frothy bloat (owner-use).	12 ounce bottle	
Target IR™ Optimized nutrition for insulin resistant and grass hay fed horses.	12 pound pail	
	36 pound pail	
ToxiBan® Activated charcoal for organic toxin adsorption.	1 pound (granules) bottle	
	5 kg/[11 lb] (granules) pail	
	240 mL (suspension) bottle –with or without sorbitol	

*Federal Law restricts these drugs to use by or on the order of a licensed veteranarian.

- One Offer per Clinic.
- Offer Valid within 90 days of Clinic Opening.
- $500 Maximum Free Goods Value.
- Qualified Purchases Must be Listed on a Single Distributor Invoice.
- Free Goods Shipped Directly from LLOYD, Inc.

LLOYD, Inc. of Iowa
P.O. Box 130
Shenandoah, IA 51601 USA
1-800-831-0004
www.lloydinc.com

midwest veterinary supply

NEW PRACTICE PROGRAM

New veterinary practices are being offered the opportunity to "Buy 1, Get 1 Free" on select Nutramax Laboratories Veterinary Sciences, Inc. products and product sizes based on the following qualifications:

- The practice must have "opened" for business within the previous 180 days from date of *New Practice Program* form submission.
  - Mobile veterinary clinicsmust present state approved premise license or similardocumentation to participate.
- All orders must be submitted and approved by the appropriate Nutramax Laboratories Veterinary Sciences, Inc. regional sales manager in order to qualify.
- Nutramax Laboratories Veterinary Sciences, Inc. products selected for the *New Practice Program* are shown on the reverse side of this form. **No other SKU's (stock keeping units) qualify for *New Practice Program*.**
- No mixing of products – "Buy 1, Get 1 Free" of like kind only. Free goods must be exactly the same SKU as the SKU purchased except where specified.
- Free goods must be shipped with the qualifying order.
- Initial purchases limited to $2,000 of Nutramax Laboratories Veterinary Sciences, Inc. products, excluding qualifying free goods associated with purchase.
  - Participating clinics can purchase an additional $2,000 in product and receive corresponding free goods upon participation in a "lunch and learn" with Nutramax Laboratories Veterinary Sciences, Inc. regional sales manager.
- This offer cannot be combined with any other product discount or product special.
- Nutramax Laboratories Veterinary Sciences, Inc. direct sales subject to Nutramax Laboratories Veterinary Sciences, Inc. shipping policy.
- Nutramax Laboratories Veterinary Sciences, Inc. reserves the right to change, modify, alter, or update the terms and conditions of the *New Practice Program*, including canceling the program at any time and without prior notice.

Clinic Name: _____

DVM/Owner(s): _____

Street Address: _____

City/State/Zip: _____

Phone: _____

Opening (or change of ownership) Date: _____

Distributor Representative: _____

Nutramax Laboratories Veterinary Sciences, Inc. Representative: _____

midwest veterinary supply

NEW PRACTICE PROGRAM

Last updated: February 2, 2024

nutramax LABORATORIES VETERINARY SCIENCES, INC.

BRAND & CATEGORY	SPECIES	FORM	ITEM	COUNT PER PACKAGE	DISP CARTON QTY	ITEM #	UNIT PRICE	QUANTITY	TOTAL PRICE	FREE GOODS
SMALL ANIMAL PRODUCTS										
AVMAQUIN™										
Wellness	Dog	Chewable Tablet	Avmaquin™	45		**AVMAQUIN45**	$17.00			
COBALEQUIN® ADVANCED										
Digestive Health	Dog (sm), Cat	Sprinkle Capsule	Cobalequin® Advanced "New Item"	45		**3000270**	$12.49			
Digestive Health	Dog (md & lg)	Sprinkle Capsule	Cobalequin® Advanced "New Item"	45		**3000271**	$15.49			
CONSIL®										
Bone Graft	Dog & Cat	Powder (cup)	Consil® Dental	2		**N0225**	$89.99			
Bone Graft	Dog & Cat	Powder (cup)	Consil® Orthopedic	1		**ON0707**	$107.99			
Bone Graft	Dog & Cat	Putty (tray)	Consil® Putty	1		**ON0602**	$58.99			
Bone Graft	Dog & Cat	Putty (tray)	Consil® Putty	1		**ON0610**	$204.99			
CRANANIDIN®										
Urinary Tract Health	Dogs	Tablet	Crananidin®	75		**CRAN75V**	$32.99			
DASUQUIN® ADVANCED										
Joint Health	Dog (sm & md)	Soft Chew	Dasuquin® Advanced With ESM	64	6	**DASUSMESADV-SC384**	$187.20			
Joint Health	Dog (lg)	Soft Chew	Dasuquin® Advanced With ESM	64	6	**DASULGESADV-SC384**	$211.50			
Joint Health	Dog (lg)	Soft Chew	Dasuquin® Advanced With ESM	140		**3000128**	$64.25			
Joint Health	Dog (sm & md)	Chewable Tablet	Dasuquin® Advanced With ESM	64		**3000167**	$28.80			
Joint Health	Dog (lg)	Chewable Tablet	Dasuquin® Advanced With ESM	64		**3000168**	$32.70			
Joint Health	Dog (lg)	Chewable Tablet	Dasuquin® Advanced With ESM	140		**3000169**	$57.49			
Joint Health	Dog (sm & md)	Soft Chew	Dasuquin® Advanced	64	6	**DASUSMSM-SC384**	$175.20			
Joint Health	Dog (lg)	Soft Chew	Dasuquin® Advanced	64	6	**DASULMSM-SC384**	$199.50			
Joint Health	Dog (lg)	Soft Chew	Dasuquin® Advanced	140	4	**DASULADV-SC560**	$248.99			
Joint Health	Dog (sm & md)	Chewable Tablet	Dasuquin® Advanced	64	6	**DASUS384ADV-MSM**	$159.90			
Joint Health	Dog (sm & md)	Chewable Tablet	Dasuquin® Advanced	140	4	**DASUS560ADV-MSM**	$208.60			
Joint Health	Dog (lg)	Chewable Tablet	Dasuquin® Advanced	64	6	**DASUL384ADV-MSM**	$185.10			
Joint Health	Dog (lg)	Chewable Tablet	Dasuquin® Advanced	140	4	**DASUL560ADV-MSM**	$222.80			
Joint Health	Cat	Sprinkle Capsule	Dasuquin® Advanced For Cats	60	6	**DASUCAT360ADV**	$83.10			
DASUQUIN®										
Joint Health	Cat	Soft Chew	Dasuquin® For Cats	84		**3000034**	$10.88			
DENAMARIN® ADVANCED										
Liver Health	Dog (sm) & Cat	Tablet	Denamarin® Advanced	30	4	**DENAMSM120-ADV**	$85.06			
Liver Health	Dog (md)	Tablet	Denamarin® Advanced	30	4	**DENAMMD120-ADV**	$115.15			
Liver Health	Dog (lg)	Tablet	Denamarin® Advanced	30	4	**DENAMLG120-ADV**	$192.71			
Liver Health	Dog	Chewable Tablet	Denamarin® Advanced	30	4	**DENAMCHWSM120-ADV**	$151.80			
Liver Health	Dog	Chewable Tablet	Denamarin® Advanced	30	4	**DENAMCHWLG120-ADV**	$212.60			
DERMAQUIN®										
Skin & Coat	Dog (sm & md) & Cat	Soft Chew	Dermaquin®	60		**DERMAQUINSM60**	$16.99			
Skin & Coat	Dog (lg)	Soft Chew	Dermaquin®	60		**DERMAQUINLG60**	$27.99			
IMUQUIN®										
Immune Health	Dog	Powder	Imuquin® for Dogs	30		**3000070**	$13.41			
Immune Health	Cat	Powder	Imuquin® for Cats	30		**3000071**	$9.99			

BRAND & CATEGORY	SPECIES	FORM	ITEM	COUNT PER PACKAGE	DISP CARTON QTY	ITEM #	UNIT PRICE	QUANTITY	TOTAL PRICE	FREE GOODS
MYCEQUIN®										
Digestive Health	Dog	Capsule	Mycequin® "Product Update"	36		**3000127**	$13.99			
NARAQUIN™										
Renal Health	Dog & Cat	Capsule	Naraquin™	60		**3000090**	$15.99			
PANZQUIN®										
Digestive Health	Dog & Cat	Powder (tub)	Panzquin®	230g		**PANZQUIN-230**	$99.00			
PROVIABLE® FORTE										
Digestive Health	Dog (sm) & Cat	Paste & Capsule	Proviable® Forte Kits	15ml/15	5	**PROVFT5KP15**	$84.50			
Digestive Health	Dog (md & lg)	Paste & Capsule	Proviable® Forte Kits	30ml/15	5	**PROVFT5KP30**	$94.50			
Digestive Health	Dog	Capsule	Proviable® Forte Capsules	45	4	**PROVFT180**	$93.80			
Digestive Health	Dog	Chewable Tablet	Proviable® Forte Chewable Tablets	45	4	**PROVFTCHW180**	$93.80			
SOLLIQUIN®										
Behaviorial Health	Dog (sm&md) & Cat	Soft Chew	Solliquin®	75		**SOLLSC75**	$11.99			
Behaviorial Health	Dog	Soft Chew	Solliquin® **"New Item"**	75		**3000230**	$15.99			
WELACTIN® ADVANCED 3TA®										
Skin, Coat & Wellness	Dog	Liquid	Welactin® Advanced 3TA®	8oz	6	**WEL3TA48**	$111.90			
WELACTIN®										
Skin, Coat & Wellness	Dog	Soft Chew	Welactin® Omega-3	60		**3000046**	$14.99			
Skin, Coat & Wellness	Cat	Liquid	Welactin® Feline	4oz		**WELCAT4**	$7.99			
EQUINE PRODUCTS										
COSEQUIN®										
Joint Health	Horse	Pellets	Cosequin® ASU	1420		**EQNASUPEL1420**	$109.99			
Joint & Hoof Health	Horse	Pellets	Cosequin® ASU Joint & Hoof	1200g		**3000007**	$84.99			
Joint Health	Horse	Powder (tub)	Cosequin® Original	280		**EQN280**	$36.06			
Joint Health	Horse	Powder (tub)	Cosequin® Original	700g		**EQN700**	$73.72			
Joint Health	Horse	Powder (tub)	Cosequin® Original	1400g		**EQN1400**	$114.99			
Joint Health	Horse	Pellets	Cosequin® Original "New Item"	910g		**3000252**	$82.99			
Joint Health	Horse	Powder (tub)	Cosequin® Optimized with MSM	1400g		**EQNMSM1400**	$84.99			
Joint Health	Horse	Pellets	Cosequin® Optimized with MSM "New Item"	1400g		**3000254**	$84.99			
Joint Health	Horse	Powder (tub)	Cosequin® ASU	500g		**EQNASU500**	$50.96			
Joint Health	Horse	Powder (tub)	Cosequin® ASU	1320g		**EQNASU1300**	$104.99			
Joint Health	Horse	Powder (tub)	Cosequin® ASU Plus	1050g		**EQNASUP1050**	$104.99			
						3000250				

QUAILIFYING PRODUCTS SUBJECT TO CHANGE WITHOUT NOTICE.

OVIK Health
9 Fanaras Drive
Salisbury, MA 01952
978.465.0044
OVIKhealth.com

New Clinic Opening Order Program
OVIK Health

New Clinic Promotional Order

- OVIK is offering a buy 1 get 1 promotion for new clinics.
- New clinics can purchase a minimum of 1 case through their Distributor and receive free OVIK product.
- OVIK will ship the free product directly to the new clinic upon receipt a copy of the invoice for the new clinic order through the distributor, minimum of 1 and maximum of 10 free cases.
- All reimbursement goods ship out of Salisbury, MA.
- Free cases will be similar the products purchased, highlighting our most popular or seasonal items determined by their OVIK Account Manager.

Invoices

- Please share a copy of the invoice to show product purchased, quantity, clinic, contact information if given (phone/email) and ship-to address.
- Distributor will send the new clinic invoices directly to their OVIK Account Manager
    - Email: Katelyn.Hussey@OvikHealth.com

Qualifiers

- One promotional new clinic order per clinic location
- Veterinary Clinics open 6 months or less at time of order
- Satellite clinics also qualify

Ovik HEALTH

midwest veterinary supply

PALA-TECH™ LABORATORIES, INC.

NEW VETERINARY PRACTICE PROMOTIONAL OFFERS

Objective: The purpose of this offer is to encourage a NEW veterinary clinic to purchase and routinely use Pala-Tech Lab's products in their practice.

Eligibility: Offers only available to *new* veterinary clinics not currently using Pala-Tech products.

Timing: The offer is available for the customer's initial purchase for these products.

Pala-Tech Product Offers:

An incentive to purchase Pala-Tech's brand is offered with free goods for each product category:

- **All Calming Extra™ Products:** Purchase one container of any Calming Extra dosage strength – Receive one container of the same product FREE.
- **Canine & Feline Joint Health:** Purchase one unit of the Granules and/or Soft Chews – Receive one unit of the same product FREE.
- **Canine & Feline F.A./Plus:** Purchase 2 units of any F.A./Plus product – Receive one unit of the same F.A./Plus product FREE.
- **Potassium Citrate Plus Cranberry Granules & Chewable Tablets:** Purchase one container of either dosage form – Receive one container of the same dosage form FREE.
- **Cranberry Plus Chewable Tablets & Granules:** Purchase one container of the Cranberry Plus Granules – Receive one bottle of the Cranberry Plus Chewable Tablets FREE.
- **Cease Coprophagia Soft Chews & Granules:** Purchase one container of either dosage form – Receive one container of the same dosage form FREE.
- **All ForSight™ Products:** Purchase one container of any ForSight formulation and package size – Receive one container of the same formulation and package size FREE.
- **Vitamin K_1 Chewable Tablets:** Purchase one bottle of the 50 mg dosage strength – Receive one bottle of the 25 mg dosage strength FREE.
- **Tricky Treats™ with MOS MAX®:** Purchase one bag or one bulk box of Roasted Chicken Flavor – Receive one bag or one bulk box of Grilled Duck Flavor FREE. Or vice versa.
- **Pala-ZYMES™ Plus Probiotics Granules:** Purchase one container of the Pala-ZYMES Plus Probiotics Granules – Receive one container of the Pala-ZYMES Plus Probiotics Granules FREE.
- **All Equine Products:** Purchase 2 units of any Pala-Tech Equine product – Receive one unit of the same Equine product FREE. Includes all Pala-Tech palatable equine product formulations.

PALATABILITY 100% ACCEPTANCE

Logistics:

- ✓ There is no restriction on the quantity of any product a customer can purchase on this offer.
- ✓ Veterinary Distributor ships all free goods with the qualifying order. Pala-Tech will issue credit or replace the free goods upon submission of documentation to Pala-Tech's office.
- ✓ All products are supported by Pala-Tech's unique 100% Palatability Acceptance Guarantee.
- ✓ Questions should be directed to Ray Cooper at Pala-Tech's office at 1-888-337-2446.

midwest veterinary supply

ZYMOX® LP3 ENZYME SYSTEM

Oratene® Enzymatic Brushless Oral Care | EQUINE DEFENSE® | ZYLAFEN®

ZYMOX® New Clinic Program

The ZYMOX New Clinic Program is available to:

- Clinics who have not purchased ZYMOX products or have a history of not purchasing for 24 months
- New veterinarians who are just starting out
- Current veterinarians who are opening another location (proof of performance must be provided by distributor)

Buy One, Get One FREE

(minimum purchase required, indicated by number in parentheses)

ZYMOX Otics

PRODUCT	MIN ORDER	SKU	UPC
Advanced Formula ZYMOX Otic PLUS w/ 1% Hydrocortisone - 1.25 oz.	(6)	1201a	6 67334 41125 6
Advanced Formula ZYMOX Otic PLUS w/o Hydrocortisone - 1.25 oz.	(6)	1201af	6 67334 42125 5
ZYMOX Otic w/ 1% Hydrocortisone - 1.25 oz.	(6)	1000	6 67334 31125 9
ZYMOX Otic w/o Hydrocortisone - 1.25 oz.	(6)	1000F	6 67334 32125 8
ZYMOX Otic w/ 1% Hydrocortisone - 4 oz.	(4)	1100	6 67334 36125 4
ZYMOX Otic w/o Hydrocortisone - 4oz.	(4)	1200F	6 67334 37125 3
ZYMOX Otic w/ 1% Hydrocortisone - 8 oz.	(2)	ZY8	6 67334 34125 6
ZYMOX Otic w/o Hydrocortisone - 8 oz.	(2)	ZYWO8	6 67334 35125 5
ZYMOX Ear Cleanser - 4 oz.	(6)	ZYC12	6 67334 33125 7
ZYMOX Advanced Enzymatic Ear Wipes - 6 oz. jar (100ct)	(6)	RZEW	6 67334 90579 3

pkb Animal Health

For more information or to place an order,
contact your authorized PKB Veterinary distributor
or email us at kdonald@petkingbrands.com or vet_sales@petkingbrands.com or call 602-882-4808

MADE IN USA

ZYMOX Topicals

PRODUCT	MIN ORDER	SKU	UPC
ZYMOX Shampoo - 12 oz.	(6)	1300	6 67334 12902 1
ZYMOX Leave-On Conditioner - 12 oz.	(6)	1400	6 67334 12903 8
ZYMOX Shampoo - 1 gallon	(1)	1300A	6 67334 13001 0
ZYMOX Leave-On Conditioner - 1 gallon	(1)	1400A	6 67334 14001 9
ZYMOX Topical Cream w/ 1% Hydrocortisone - 1 oz.	(6)	ZYTC	6 67334 12905 2
ZYMOX Topical Cream w/o Hydrocortisone - 1 oz.	(6)	ZYTCWO	6 67334 12908 3
ZYMOX Topical Spray w/ 1% Hydrocortisone - 2 oz.	(6)	ZYTS	6 67334 12904 5
ZYMOX Topical Spray w/o Hydrocortisone - 2 oz.	(6)	ZYTSWO	6 67334 12907 6

Oratene® Enzymatic Brushless Oral Care

PRODUCT	MIN ORDER	SKU	UPC
Oratene Brushless Oral Care Starter Kit	(12)	OVOCK	6 67334 60200 5
Oratene Oral Gel - 1 oz.	(6)	ROCAG0100	6 67334 60100 8
Oratene Brushless Toothpaste Gel - 2.5 oz.	(6)	RODG0250	6 67334 50250 3
Oratene Breath Freshener - 4 oz.	(6)	ROBF0400	6 67334 50400 2
Oratene Water Additive - 4 oz.	(6)	ROWA0400	6 67334 50401 9
Oratene Water Additive - 8 oz.	(4)	ROWA0800	6 67334 50800 0

ZYMOX Specialty Pets

PRODUCT	MIN ORDER	SKU	UPC
ZYMOX Small Animal & Exotic Topical Solution w/o Hydrocortisone - 1.25 oz.	(6)	RZSMESS	6 67334 43125 4
ZYMOX Small Animal & Exotic Topical Spray w/o Hydrocortisone - 2 oz.	(6)	RZSMETS	6 67334 44000 3
Zylafen Topical Solution w/o Hydrocortisone - 1.25 oz.	(6)	RZZSS	6 67334 81000 4
Zylafen Topical Spray w/o Hydrocortisone - 2 oz.	(6)	RZZTS	6 67334 82000 3
ZYMOX Avian Care Topical Solution w/o Hydrocortisone - 1.25 oz.	(6)	RZBSS	6 67334 45125 2
ZYMOX Avian Care Topical Spray w/o Hydrocortisone - 2 oz.	(6)	RZBTS	6 67334 46000 1

Equine Defense®

PRODUCT	MIN ORDER	SKU	UPC
Equine Defense Advanced Formula Shampoo - 12 oz.	(6)	REDAFS1200	6 67334 71100 4
Equine Defense Advanced Formula Shampoo - 1 gallon	(1)	REDAFS128G	6 67334 71110 3
Equine Defense Advanced Formula Leave-on Conditioner - 12 oz.	(6)	REDAFC1200	6 67334 71101 1
Equine Defense Advanced Formula Leave-On Conditioner - 1 gallon	(1)	REDAFC128G	6 67334 71111 0
Equine Defense Topical Cream - 2.5 oz.	(6)	REDWSC0250	6 67334 70103 6
Equine Defense Topical Spray - 8 oz.	(6)	REDWSS080	6 67334 70102 9

Must purchase 2 deals for "Buy One, Get One Free". Rebate of $200 used for future purchase within 90 Days of receipt of order. Proof of new clinic and deal purchase required. No changes or substitutions unless prior approval by PKB. Cannot be combined with any other promotions or discounts.

pkb Animal Health

For more information or to place an order, contact your authorized PKB Veterinary distributor or email us at kdonald@petkingbrands.com or vet_sales@petkingbrands.com or call 602-882-4808

MADE IN USA

midwest veterinary supply

PRN® Pharmacal

New Practice Program

Program Guidelines

Partcipants: Veterinarians starting a new clinic, a clinic under new ownership or the opening of a new branch location on or after **January 1, 2025** ("New Clinic").

- **New Clinic qualifying Order must be verified by a PRN® Pharmacal Sales Representative.**
- New Clinic must place a qualifying initial stocking order ("Order") through an authorized PRN Pharmacal distributor.
- Order must be dated within 3 months prior to opening or 3 months after opening of New Clinic (same for establishing new ownership).
- New branch locations or satellite clinics qualify only if Order is shipped to new location.
- Limit one (1) qualifying Order per New Clinic.
- May not be combined with any other PRN Pharmacal promotional programs.
- Distributor purchase invoice must be attached and submitted with New Practice Program Claim Form (*see reverse side*) to PRN Pharmacal.

Program Details

PRN® Pharmacal Products: Purchase two (2) individual items of like product, receive one (1) item of the same product free, subject to:

- Minimum qualifying order of $500 in purchased PRN Pharmacal products.
- Maximum qualifying order of $20,000 in purchased PRN Pharmacal products.

Terms & Conditions

This promotion is restricted to veterinary practices where the veterinary-client-patient relationship (VCPR) exists as defined by the AVMA's Principles of Veterinary Medical Ethics. Other veterinary accounts such as shelters, animal care/control agencies and veterinary partner pharmacies, may be eligible on a case-by-case basis. Accounts with direct-to-consumer sales via internet website, catalog or other over-the-counter channels are ineligible. Qualifying orders must be on a single invoice. Free goods will be fulfilled by distribution at the time of purchase. Free goods may not be returned for credit. PRN Pharmacal reserves the right to modify or withdraw this promotion at any time. Promotion excludes Canada, Mexico and the Caribbean Islands.

PRN® PHARMACAL

PRN® Pharmacal
New Practice Program

Enrollment* Form

Please submit this enrollment form prior to first order to: **prnprograms@prnpharmacal.com**

☐ **New Practice** ☐ **New Owner** ☐ **New Branch**

Veterinary Clinic Name:		
Veterinary Clinic Owner:		
Clinic Contact:	**Clinic Phone:**	
Clinic Address:		
City:	**State:**	**Zip:**
Email Address:		
Number of Veterinarians at this Location:	**Clinic Opening Date:**	
Distributor Company Name:	**Distributor Rep Name:**	
PRN Pharmacal Regional Sales Representative Signature:		

PRN® Pharmacal, an employee-owned company, has been dedicated to developing specialized therapeutics that address the unmet, underserved and overlooked needs of the veterinary medicine community since 1978. Our commitment: quality solutions – as needed, when needed.

If there are any questions regarding this program, please contact your PRN Pharmacal Regional Rep.

PRN®Pharmacal | 8809ElyRoad | Pensacola,FL32514 | 800.874.9764 | prnpharmacal.com

PRN® PHARMACAL

midwest veterinary supply

Contact your Midwest Veterinary Supply Representative for more information!
To place your order: 1-800-643-9378 | www.midwestvetsupply.com

midwest veterinary supply

NEW PRACTICE PROMOTION

20% OFF INITIAL STOCKING ORDER

PROOF WILL BE REQUIRED TO VERIFY ELIGIBILITY

LIMITED TO:

- *EXISTING CLINICS THAT OPEN A SECOND LOCATION*
- *BRAND NEW CLINICS*
- *NEW LOCATION OPENINGS*
- *NEW OWNERS OF CLINICS*

Promotion Start Date:

- JULY 1, 2025

Promotion End Date:

- ONGOING (Van Beek Natural Science may terminate this promotion at any time)

How to Redeem:

- Submit proof of eligibility to issuing distribution partner
- A promo code or custom invoice will be issued after approval
- Must place order within 30 days of approval to receive discount

Limitations:

- One-time use per new clinic location
- Cannot be combined with other offers
- Applies to first order only
- Offer subject to approval and inventory availability

VAN BEEK® NATURAL SCIENCE